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ABSTRACT
Recent developments in the field of cancer genomics have shown transcription factor
HIF-1α as a major player in the survival and proliferation of colorectal tumors. Hypoxia targeted
drug engineering has led to significant advancements in cancer treatments as a method of directly
utilizing the hypoxic regions against the tumor. Novel drug DCQ (2-benzoyl-3-phenyl 6,7dichloroquinoxaline 1,4-dioxide) has shown promising anti-tumor results in-vitro and in-vivo.
The purpose of this study was to utilize a tumor xenograft and genetic mouse model of colorectal
cancer to investigate the safety, clinical effectiveness, and mechanism of action of DCQ.
Methods: 10 week old Balb/c mice were injected subcutaneously with 2 million CT-26 cells and
were monitored for tumor growth over 14 days before receiving treatment. Apcmin/+ mice were
clinically evaluated from 8 weeks of age and began treatments at 16 weeks of age. DCQ
treatment given at a 17mg/kg dose and 100μL DMSO injection as control. Injections were given
bi-weekly over a four week period. Results: DCQ caused significant decrease in tumor weight
(p<0.05) and final tumor area (p<0.05) in Balb/c mice at time of sacrifice than control and
Apcmin/+ mice showed significantly lower clinical score after 1 week of therapy along with
decreased large tumor size (p<0.05) and number (p<0.05). Histological analysis showed
increased total apoptotic area (p<0.05) in tumor tissue sections and tumor specific apoptosis in
colon tissue in both models. Western blot analysis of Balb/c showed a decreased nuclear
expression of HIF-1α (p<0.05) and increased expression of pro-apoptotic genes
dephosphorylated-Bad (p<0.001), cleaved caspase-9 (p<0.05), and Bax (p<0.05) paralleled with a
decrease in anti-apoptotic Bcl-2 gene (p<0.05). Conclusions: DCQ induces tumor specific
apoptosis through mechanisms involving down regulation of HIF-1α and increased intracellular
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apoptosis in Balb/c mice and Apcmin/+ mice. Novel drug DCQ may potentially have use as a
chemotherapeutic agent to reduce the pathology of sporadic intestinal and colorectal cancers.

KEYWORDS: Cancer, Colon, DCQ, Drug
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CHAPTER 1
INTRODUCTION AND AIMS
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In 2012 the WHO reported cancer as the leading cause of death worldwide
accounting for nearly 8.2million deaths. In the United States, cancer related deaths were
reported as second highest behind heart disease (Torre et al., 2015). Colorectal cancer is
the second most prevalent cancer in both men and women in the United States in terms of
incidence and death rates. The American Cancer Society estimates approximately 51,000
Americans will die of colon cancer and nearly 150,000 new cases will be diagnosed in
2014 (Siegel, DeSantis, & Jemal, 2014). It is currently estimated that the average
American has a 5% lifetime risk of developing colorectal cancer and men are at higher
risk than women are with a morbidity rate of 59 per 100,000 people versus 44 for women.
The incidence of colorectal cancer increases with advancing age in both genders, with the
highest risk occurring in those over 69 years of age. The financial burden of colorectal
cancer has had a large impact on the current health care system. In 2010, the direct cost
of colorectal cancer was estimated to be $12.2 billion dollars, $10.7 being due to lost
productivity and premature death (Siegel et al., 2014; Torre et al., 2015). Thus, colorectal
cancer has had a major impact on both the economy and population of the United States.
The initial incidence of hypoxia in the tumor environment arises because of
oxygen diffusion limitations in avascular primary tumors (Lunt, Chaudary, & Hill, 2008;
Mathonnet et al., 2014; Ryan, Lo, & Johnson, 1998; Zeng, Liu, Pan, Singh, & Wei,
2014). As a result of increased hypoxia in the tumor environment, the tumor
microvasculature proliferates and serves to benefit tumor growth and metastasis. Normal
responses to hypoxia typically see increased microvasculature proliferation in the tissue
but with eventual compensation by the body through increased red blood cell count and
increased oxygen carrying capacity of the blood (Lunt et al., 2008; Yasuda, 2008). In the
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tumor environment, the increased microvasculature proliferation in the tumor tissue is
highly abnormal and often fails to correct for the oxygen deficit. This persistent hypoxia
leads to spatial disorganization of the tumor vascular networks and eventually leads to
intercapillary distances that are beyond the diffusion range of oxygen (~200μm)
(Brocato, Chervona, & Costa, 2014; Kunz & Ibrahim, 2003).
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that
plays a critical role in the cellular response to hypoxia. HIF-1 was discovered by the
identification of a hypoxia response element (HRE; 5′-RCGTG-3′) in the 3′ enhancer of
the gene for erythropoietin (EPO), a hormone that stimulates erythrocyte proliferation
and undergoes hypoxia-induced transcription (Semenza, Nejfelt, Chi, & Antonarakis,
1991). HIF-1 regulates the transcription of a broad range of genes that facilitate responses
to a hypoxic environment, including genes regulating angiogenesis, erythropoiesis, cell
cycle, metabolism, and apoptosis. The HIF-1 complex consists of two subunits, HIF-1α
and HIF-1β, both of which are basic helix-loop-helix proteins of the PAS family. HIF-1α
in seen to accumulate under hypoxic conditions whereas HIF-1β is constitutively
expressed in both hypoxic and normoxic conditions. When expressed under hypoxic
conditions, HIF-1α is seen to play a vital role as a mediator for solid tumor expansion
including activation of angiogenic factor VEGF. HIF-1β is the Aryl hydrocarbon
Receptor Nuclear Translocator (ARNT), which is essential for the xenobiotic response
(Wolff et al., 2013). Under normoxic conditions, undifferentiated HIF-1 is targeted by an
E3 ubiquitin ligase containing the von Hippel Lindau protein (VLH). The human genome
contains EGL9 (Egg Laying Nine-9) homologues that are named EGLN1, EGLN2, and
EGLN3 (also known as PHD2, PHD1, and PHD3 respectively). Prolyl Hydroxilase
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domain- containing proteins (PHDs) post-translationally modify HIF-1, allowing
interactions with VHL to occur. All three proteins of PHDs can hydroxylate HIF-1α at
one of two proline sites within the ODDD (Pro-402 and Pro-564). VHL is part of a larger
protein complex that includes Elongin-B, Elongin-C, Cul2, RBX1, and a ubiquitinconjugating enzyme (E2). This complex, along with ubiquitin-activating enzyme (E1),
regularly mediates ubiquitylation of HIF-1 and its subunits (Ke & Costa, 2006).
In hypoxic conditions, HIF-1α subunits are not recognized by pVHL, this leads to
accumulation of HIF-1α which dimerize with HIF-1β and translocate into the nucleus. In
the nucleus, these proteins act as transcriptional regulators with cofactors such as
CBP/p300 and DNA polymerase II complex to bind to hypoxia-responsive elements
(HREs) and activate transcription of target genes. The understanding of HIF-1α target
genes is well understood, HIF-1α-activated genes include Vascular Endothelial Growth
Factor (VEGF), Glucose Transporter-1 (GLUT1), Lactate Dehydrogenase (LDHA),
Ertythropoietin (EPO), and Nitric Oxide Synthase (NOS) (He, Jiang, Zhang, & Wu,
2014; Zeng et al., 2014).
Defective apoptosis is frequently associated with malignancies originating from
B-lymphocytes. Bcl-2 family proteins govern the mitochondrial outer membrane
permeabilization (MOMP) in the intrinsic regulation of apoptosis. In the presence of a
trophic factor, PI-3K is activated and leads to the activation of protein kinase B (PKB or
Akt) which hydrolyzes ATP to phosphorylate pro-apoptotic protein Bcl-2-associated
death promoter (Bad). Phosphorylated BAD at this point forms a 14-3-3 heterodimer
which prevents its binding to Bcl-2 which leaves Bcl-2 to form a heterodimer with BclxL. The formation of this dimer does not allow for the formation and opening of Bax/Bak
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heterodimer ion channel to promote the release of cytochrome c to the cytoplasm.
Absence of cytochrome c does not allow for the formation of the cytochrome c/APAF1/procaspase-9 multiprotein complex which does not allow for the initiation of apoptosis.
Therefore, apoptosis is actively inhibited through the blocking of this mechanism which
is stimulated by the presence of a trophic factor (Erler et al., 2004; Wei et al., 2001; Xin
& Deng, 2006; Zhang et al., 2004).
Quinoxaline di-N-oxides (QdNOs) were approved in the late 1960's for use as
feed additives in livestock farming to promote animal growth and as an effort to replace
banned therapeutic antibiotics, penicillin, and tetracyclines (Diab-Assef, Haddadin,
Yared, Assaad, & Gali-Muhtasib, 2002; Gali-Muhtasib, Diab-Assaf, & Haddadin, 2005).
Approval of QdNOs for use was due to the large body of evidence showing that
quinoxaline antibiotics are inhibitors of DNA synthesis and had increased effectiveness
in anaerobic conditions. The structural design of QdNOs is the key to the increased
effectiveness of DNA synthesis inhibition in these types of antibiotics. In the presence of
an electron rich environment, a free radical intermediate is created by the transfer of an
electron from this electron rich environment to the electron-poor nitrogen centers of the
1,4-di-N-oxide moiety. In a hypoxic environment, this transfer is more likely to occur due
to the highly reducing conditions of hypoxic cells, leading to hypoxic cells acting as a
targeting element to cytotoxicity of these compounds (Diab-Assef, Haddadin, Yared,
Assaad, & Gali-Muhtasib, 2002; H. U. Gali-Muhtasib, Diab-Assaf, & Haddadin, 2005).
Administration of quinoxaline di-N-oxides to tumor cultures has shown promising
evidence of tumor specific apoptosis and decreased proliferation through interactions
with the HIF-1α pathway. Preliminary research from the American University of Beirut

5

has shown tumor specific cytotoxicity mechanisms of quinoxaline 1,4-dioxides (QdNOs)
cultured under hypoxic conditions. The QdNOs were found to possess a 50- to 100- fold
greater cytotoxicity to human T-84 colorectal cells cultured under hypoxia compared to
an oxic environment. It was reported that the hypoxia cytotoxicity ratio (HCR), the ratio
of equitoxic concentrations of the drug under aerobic/anoxic condition, was highly
structure related and dependent on the nature of the substituents' on the QdNO
heterocycle. The most cytotoxic, 2-benzoyl-3-phenyl-6,7-dichloro derivative of the
quinoxaline 1,4-dioxide, or DCQ, was potent at a dose of 1μM with an HCR of 100 and
significantly reduced the levels of HIF-1α transcript and protein. It was further
hypothesized that the C-6 and C-7-chlorine of DCQ might play a significant role in the
selective hypoxic cytotoxicity of the drug (Diab-Assef et al., 2002; H Gali-Muhtasib et
al., 2000).
Administration of DCQ in both tumor cell cultures and healthy epithelial cells at
concentrations of 5μM and 10μM show promising results to tumor specific induction of
apoptosis via HIF-1α pathway and up-regulation of pro-apoptotic apoptosis genes (ElKhatib et al., 2010; H. U. Gali-Muhtasib et al., 2005; Ghattass et al., 2014). While there
is evidence of direct effectiveness of DCQ in cell cultures and a suggested safe
concentration of 17mg/kg, there is still an incomplete understanding of the in-vivo
effectiveness, overall safety, and direct mechanisms of action that account for the tumor
specific targeting of DCQ. The overall goal of this proposal is to determine clinical
effectiveness of DCQ in inducing apoptosis of colorectal tumor cells and systemic safety
of the 17mg/kg dosage in an implant and genetic model of colorectal cancer. Our central
hypothesis is that DCQ administered at a concentration of 17mg/kg will be effective at

6

reducing tumor size and burden in both models of colorectal cancer and reduce HIF-1α
expression leading to up-regulated tumor specific mitochondrial induced apoptosis
without showing signs of systemic toxicity.
Specific Aim #1 will evaluate the safety and effectiveness of the 17mg/kg DCQ dosage
in a xenograft and genetic model of colorectal cancer.
Specific Aim #2: will determine the mechanism of action of DCQ in the two animal
models of colorectal cancer.
Working Model: Initially the proposal will examine the overall effectiveness of DCQ on
decreasing tumor burden and improving animal health of the 17mg/kg dosage in a CT-26
xenograft model and Apcmin/+model of colorectal cancer (AIM 1). Next, the proposal will
examine if DCQ therapy works through similar mechanisms in both models to induce
tumor specific apoptosis (AIM 2). The Apcmin/+ and CT-26 xenograft animal models
differ in rate of cancer progression and overall clinical tumor burden relative to body
size, however both serve as effective models of studying colorectal cancer.
Understanding the effectiveness of DCQ in both a xenograft and genetic model of
colorectal cancer will serve as an important step for progression of DCQ to human trials
in addition to furthering our understanding of the role of QdNOs in the prevention and
treatment of colorectal cancer.
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Figure 1.1 Working Model

8

Specific Aim #1 will evaluate the safety and effectiveness of the 17mg/kg DCQ
dosage in a xenograft and genetic model of colorectal cancer.
Rationale: It has been previously shown that DCQ is effective in causing tumor
specific apoptosis and can repress tumor growth in multiple human cancer cell lines
through activation mechanisms involving down-regulation of HIF-1α pathway (DiabAssef et al., 2002; El-Khatib et al., 2010; Ghattass et al., 2014; H. U. Gali-Muhtasib et
al., 2005; Haykal et al., 2008, 2009). Toxicity studies from the American University of
Beirut have suggested a concentration of 17mg/kg dose will be effective in causing tumor
cell apoptosis while staying below systemic toxic levels, therefore preserving essential
healthy tissue in both the GI system and the entire body. The 17mg/kg dosage has
previously been shown to be effective in a breast cancer xenograft study, however, there
is lack of clinical data from this study and DCQ has yet to be investigated in-vivo for
clinical effectiveness in a colorectal cancer model (Ghattass et al., 2014). Thus, we would
like to investigate the safety and clinical effectiveness of the 17mg/kg dose in a tumor
implant and genetic model of colorectal cancer.
Aim 1.1: Observation of tumor size and weight in Balb/c mice implanted with
CT-26 tumor xenografts over a four week therapy period with DCQ
administration at a concentration of 17mg/kg.
Aim 1.2: Clinical score of Apcmin/+ mice over a four week therapy period with
DCQ administration at a concentration of 17mg/kg.
Aim 1.3: Safety of DCQ will be determined by assessment of other vital organs
for presence of increased apoptosis and abnormal phenotype
9

Specific Aim #2: will determine the mechanism of action of DCQ in the two animal
models of colorectal cancer.
Rationale: Studies in multiple human cell lines from the American University of
Beirut have shown consistent results of increased mitochondrial induced apoptosis with
DCQ treatment. The CT-26 xenograft and Apcmin/+ transgenic mouse are common
experimental models of colorectal cancer. The mutated Apc gene causes activation of the
Wnt/β-catenin pathway which is responsible for tumorgenesis in the colon and small
intestines (Bienz & Clevers, 2000; Leclerc, Deng, Trasler, & Rozen, 2004; Newton,
Kenneth, Appleton, Näthke, & Rocha, 2010; Näthke & Rocha, 2011). Although this is a
specific genetic model of cancer there is genetic variability in the tumor formation and
therefore each tumor site is expected to respond differently to drug treatment. HIF-1α and
the Apc gene have been shown to have cross-communication at the transcriptional level
which serves as a driving force for intestinal tumorgenesis (Mehl et al., 2005; Newton et
al., 2010; Yamulla et al., 2014). Since it has been determined that DCQ works through
interruption of the HIF-1α pathway, we are interested in mechanistic differences between
and within the murine CT-26 tumor xenograft model and Apcmin/+ genetic model of
colorectal cancer.
Aim 2.1: Activation of DCQ will be determined through expression of HIF-1α.
Decreased HIF-1α will indicate the hypoxic environment of the tumor
environment is promoting transformation of DCQ to its active intermediate.

10

Aim 2.2: Presence of tumor specific apoptosis and expression of pro-apoptotic
and anti-apoptotic genes will be performed to compare between the two models of
colorectal cancer and indicate mechanisms of mitochondrial induced apoptosis.
Aim 2.3: Histological analysis of tumor containing sections of colon and intestine
in Apcmin/+ mice will indicate tumor specific induction of apoptosis by DCQ.
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CHAPTER 2
REVIEW OF LITERATURE
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2.1 Colorectal Cancer
In 2012 the WHO reported cancer as the leading cause of death worldwide
accounting for nearly 8.2million deaths. In the United States, cancer related deaths were
reported as second highest behind heart disease (Torre et al., 2015). Colorectal cancer is
the second most prevalent cancer in both men and women in the United States in terms of
incidence and death rates. The American Cancer Society estimates approximately 51,000
Americans will die of colon cancer and nearly 150,000 new cases will be diagnosed in
2014 (Siegel et al., 2014). It is currently estimated that the average American has a 5%
lifetime risk of developing colorectal cancer and men are at higher risk than women are
with a morbidity rate of 59 per 100,000 people versus 44 for women. The incidence of
colorectal cancer increases with advancing age in both genders, with the highest risk
occurring in those over 69 years of age. The financial burden of colorectal cancer has had
a large impact on the current health care system. In 2010, the direct cost of colorectal
cancer was estimated to be $12.2 billion dollars, $10.7 being due to lost productivity and
premature death (Siegel et al., 2014; Torre et al., 2015). Thus, colorectal cancer has had a
major impact on both the economy and population of the United States.
Clinical Symptoms of Colorectal Cancer
Colorectal cancer is a degenerative disease that takes years to develop in the
humans. Incidence of colorectal cancer is suggested to be onset by chronic stress and
poor lifestyle management, the latter of which is typically a lack of physical activity and
poor diet. In the early stages of the disease, symptoms of colorectal cancer may be
minimal or not present at all. The quantity and severity of symptoms associated with
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colorectal cancer typically accompany the progression of the disease. In a clinical setting,
symptoms of colorectal cancer are broken down into local and systemic. Local symptoms
are those which have a direct effect on the colon or rectum and are seen in the various
stages of the disease. These symptoms include changes in bowel habits, constipation,
diarrhea, alternating diarrhea and constipation, rectal bleeding or bloody stools,
abdominal bloating or cramping, incomplete bowel emptying, and thinner stools.
Systemic symptoms are those that effect the entire body and are typically seen in the later
stages of the disease. These symptoms include unexplained weight loss, unexplained loss
of appetite, nausea or vomiting, anemia, jaundice, and weakness and fatigue. Due to the
delayed onset of both local and systemic symptoms past the initial onset of the disease
regular screening is recommended on a per 5 year basis for everyone over 50 years old.
2.2 Models of Studying Colorectal Cancer
There are many models of studying colorectal cancer that are being utilized to
understand and investigate development, progression, and potential therapies of the
condition. Utilization of both genetic and tumor implantation models are common in
animal research. Cell culture methods have also been utilized, especially for drug
development, to understand a direct impact of a specific factors and secreted cytokines on
proliferative and necrotic regulation. Human models are only used in later progressions
of drug development, therefore many investigators use rodent or in vitro models to study
treatments and mechanisms involved in colorectal cancer.
Non-rodent species
Canine use has become attractive model for comparative oncology research.
Similar to rodent models, there are many similarities between canine colorectal cancer
14

and the human disease. One of the benefits to canine intestinal cancer models is the onset
of tumors is more commonly found in the large intestine rather than the small intestine.
This more closely mimics the descending colon/rectal cancers that are most frequently
seen in human onset of the disease (Johnson & Fleet, 2013). Evaluations of canine
colorectal adenomas have revealed cytoplasmic and nuclear accumulation of β-catenin,
which further suggests a dysregulation of the WNT signaling pathway is an important
driver in the onset of colorectal cancer in canine species (McEntee & Brenneman, 1999).
Despite the similarities between canine and human colorectal cancer, the prevalence in
canines is less than 1% and therefore severely limits the effectiveness of using this model
(Johnson & Fleet, 2013; McEntee & Brenneman, 1999).
Sheep are also an effective model of studying human colorectal cancer due to the
similarities of lesions and metastatic behavior between the human disease. Despite this
similarity, it has been shown that 100% of the intestinal adenocarcinomas developed in
sheep are found in the small intestine. Along with this limitation, the unique
physiological characteristics of the sheep ruminant forestomachs has been shown as a
significant weakness of this model (Johnson & Fleet, 2013; Munday, Brennan, Jaber, &
Kiupel, 2006).
CT-26 Adenocarcinoma
Another commonly used model is the CT-26 adenocarcinoma model of colorectal
cancer. CT-26 cells can either be cultured or injected subcutaneously in Balb/c mice,
which is known as a Xenograft model. Tumors typically develop within 14 days and the
mice begin to show severe symptoms of tumor burden. While other animal models
develop multiple intestinal polyps over the course of time, the CT-26 Xenografts develop
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into large visible tumors that can account for more than 15% of the animal's total body
weight. This model typically mimics the symptoms of tumor burden which include
increased circulating IL-6 and insulin resistance (Aulino et al., 2010). Since this model
typically shows hallmarks of human cancer conditions and allows for rapid studies to be
conducted, it is often incorporated in preliminary studies for drug and therapy
development. The accelerated development of the large tumor makes the tumor burden
less like the human condition, but is still valid as a model of studying colorectal cancer
(Aulino et al., 2010; Bonetto et al., 2011, 2012).
Diet-Induced Rodent Neoplasia Models
Epidemiological evidence has shown diet as a key modulator to the incidence of
colorectal cancer in humans (Lee et al., 2012, 2013; Magalhães, Peleteiro, & Lunet,
2012; Shivappa et al., 2014). Several rodent studies have been conducted to examine the
influence of poor diet on the incidence of colorectal cancer. This diet typically is
designed to mimic the poor "Western diet" that has become problematic to the current
health of many Americans. There are several modifications of a western diet. The
"Western diet" is designed to increase dietary fat intake from 5% to 20%, decrease
dietary calcium from 0.5% to 0.05%, and decrease vitamin D intake to 100 IU/kg from
1,000 IU/kg (Johnson & Fleet, 2013; Newmark, Lipkin, & Maheshwari, 1990). Feeding
the Western diet for as little as 12 weeks was shown to induce hyperplasia of colonic
crypts in rats and mice (Newmark et al., 1990). Longevity studies have also shown that
after 2 years of being fed the Western diet, 70% of the mice developed dysplastic crypts
and small polypoid lesions, most of which were found in the distal colon (Risio et al.,
1996). Another study has also shown that a 2 year feeding of a Western diet low in fiber,
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folate, methionine, and choline content lead to 25% of C57BI/6J mice developing
intestinal tumors and showed lesions demonstrating evidence of adenocarcinoma
(Johnson & Fleet, 2013; Newmark et al., 2001; Risio et al., 1996). Feeding the Western
diet to mice has also been shown to induce a transcript profile in normal colonic mucosa
that was similar to the pattern loss of Apc allele in Apc138N/+ mice (Yang et al., 2008). The
Western diet model of spontaneous colorectal cancer is an attractive model however the
changes in physiology seen in many studies do not reflect the etiology of human
colorectal cancer (Johnson & Fleet, 2013).
Chemical-Induced Models
A large number of chemicals have been shown to have mutagenic potential and
are used to controllably induce cancer. 1,2-dimethylhydrazine (DMH) and its metabolite
azoxymethane (AOM), are the two most commonly used carcinogens to induce colorectal
cancer in rodents (Bissahoyo et al., 2005). DMH and AOM are alkylating agents that are
typically injected intraperitoneally or subcutaneously over several weeks to induce
tumorgenesis. The majority of these tumors are seen in the distal colon and are seen to
harbor mutations in the β-catenin gene. This mutation affects the N-terminal amino acids
of the β-catenin gene product and leads to resistance of the regulatory degradation, this
stabilizes β-catenin and increases WNT signaling to drive tumor development (Bienz &
Clevers, 2000; Komiya & Habas, 2008; Sebio, Kahn, & Lenz, 2014). This model
therefore is useful for studying the gene-gene and gene-environment interactions that
influence the pathophysiology of colorectal cancer. However it is suggested that this
model is not viable due to the little evidence supporting the induction of human colorectal
cancer resulting from exposure to alkylating agents (Johnson & Fleet, 2013).
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Apcmin/+
The Apcmin/+ mouse has been one of the leading models for preclinical colorectal
cancer research over the past 20 years. The phenotype of these mutant mice showed
severe clinical symptoms of intestinal cancer from the onset of a usually fatal case of
regenerative anemia attributed to multiple intestinal neoplasms, or "Min." The Min
mouse has a naturally occurring T-to-A nonsense mutation at nucleotide 2,549 of the
Adenomatous polyposis coli (Apc) gene that pares the Apc protein at the codon 850, this
predisposes the mice to multiple intestinal adenomas (Moser, Pitot, & Dove, 1990) . The
Min mutation is autosomal dominant, and homozygosity for the mutant allele is
embryonic lethal. Heterozygous Apcmin/+ mice typically become anemic by 60 days of
age and progress through worsening clinical symptoms of intestinal cancer and usually
die by 120 days of age (Johnson & Fleet, 2013; Moser et al., 1990).
The use of the Apcmin/+ mouse model has been widely used to study
carcinogenesis or to test a developing treatment and delivery methods, the Apcmin/+
mouse has also been used to study genetic modifiers of colorectal cancer risk or
Modifiers of Min (Mom) (Balmain, Gray, & Ponder, 2003; Johnson & Fleet, 2013).
2.3 Chemotherapy Treatments
Current chemotherapy treatments have undergone a significant improvement in
tumor cell targeting over the last 60 years. Since the discovery of the DNA replication
blocking mechanisms of Aminopterin, the predecessor of current treatment methotrexate,
research into blockading functions of cell growth have been the major focus for the
development of anti-cancer therapies. As the incidence of different types of cancer was
evolved in the medical community, there was an increased demand of treatment methods.
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Present therapies are able to be controlled with early detection and regular
chemotherapies. As various mechanisms of cancer development and treatment were
discovered, so paralleled the evolution of chemotherapy treatments. The development of
chemotherapy treatments have begun to focus on drug combinations, delivery techniques,
tissue specificity, and overcoming drug resistance by carcinomas (Brown & Wilson,
2004; McKeown, Cowen, & Williams, 2007; Silvestris et al., 2013).
The medical field has seen significant advancements in chemotherapy treatments
over the last 40 years, however, one of the most common problems in drug design is the
engineering of compounds to attack specifically the tumor environment and malignant
tissue sites. Clinically, it is seen that many chemotherapy treatments can improve clinical
score and wellbeing of the patient but have detrimental effects to healthy tissue. Many of
the detrimental effects of chemotherapy treatments can be attributed to the non-specific
targeting of tissue by the drug compound. The toxic effects of these compounds increases
stress on the body and can ultimately lead to death in the patient (Bai & Wang, 2014;
Gogvadze, Orrenius, & Zhivotovsky, 2009; Mathonnet et al., 2014; McKeown et al.,
2007; Pettersen et al., 2014; Silvestris et al., 2013).
Phases of Drug Development
The progression of drug testing requires many pre-clinical and clinical steps that
are highly regulated by the FDA. The first step in drug development is pre-clinical animal
and in vitro based experiments that show effective and safe delivery methods and propose
methods for progression to human testing. At this stage, the FDA can decide whether the
drug is reasonably safe for progression to human trials or to take the drug back to
formula. Once in clinical trials the drug is considered an investigational new drug and
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must pass three phases of clinical testing that are overseen by both medical research and
non-research based scientists and physicians.
Phase 1 testing is usually conducted in healthy volunteers in an effort determine
frequent side effects and how the drug is metabolized and excreted. The typical number
of subjects for this phase is usually between 20 and 80. Phase 2 studies begin once the
drug is determined safe for healthy humans and experiments begin to focus on drug
effectiveness in humans. This phase tests a variety of patients with certain diseases or
conditions and is compared in a controlled study against a placebo drug or current form
of treatment. In Phase 2, the number of subjects can be expanded to at most 300 and is
usually determined based on the range of conditions being investigated. At the end of
Phase 2, if a drug has shown evidence of effectiveness in a certain population, Phase 3
can be initiated as a follow-up study with larger subject populations. The number of
subjects in Phase 3 can be anywhere from a few hundred to 3,000. After passing all three
phases of human clinical trials, postmarket and commitment studies are required by a
sponsor and are monitored by the FDA. This typically allows the drug to enter longevity
studies in humans to determine any long term side effects that may arise from continuous
use of the drug. Once passed by the FDA the drug can be submitted to the FDA as a new
drug and within six months the drug can be passed and distributed for use in clinical
medicine (Kinch, 2014).
2.4 Hypoxia in the Tumor Microenvironment
The progression of tumor development in colorectal cancer shows a wide range of
abnormal physiological characteristics that aide in the maintenance of tumor tissue. As a
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solid tumor grows, the rate of cancerous cell proliferation surpasses the ability of the
existing vasculature to supply growth factors, nutrients, and oxygen and to remove the
catabolic waste produced by these cells. The result of these events is a change in the
tumor environment and leads to an imbalance between supply and demand (Cairns,
Harris, & Mak, 2011; Faubert et al., 2014). Accompanying this change introduces regions
of hypoxia, low glucose, and low pH (Kunz & Ibrahim, 2003; Lunt et al., 2008; Ryan et
al., 1998; Zeng et al., 2014). Most solid tumors contain hypoxic or anoxic regions that are
believed to contribute to local resistance to therapy treatments in addition to promoting
tumor metastasis.
Hypoxia
The initial incidence of hypoxia in the tumor environment arises because of
oxygen diffusion limitations in avascular primary tumors (Lunt et al., 2008; Mathonnet et
al., 2014; Ryan et al., 1998; Zeng et al., 2014). As a result of increased hypoxia in the
tumor environment, the tumor microvasculature proliferates and serves to benefit tumor
growth and metastasis. Normal responses to hypoxia typically see increased
microvasculature proliferation in the tissue but with eventual compensation by the body
through increased red blood cell count and increased oxygen carrying capacity of the
blood (Lunt et al., 2008; Yasuda, 2008). In the tumor environment, the increased
microvasculature proliferation in the tumor tissue is highly abnormal and often fails to
correct for the oxygen deficit. This persistent hypoxia leads to spatial disorganization of
the tumor vascular networks and eventually leads to intercapillary distances that are
beyond the diffusion range of oxygen (~200um) (Brocato et al., 2014; Kunz & Ibrahim,
2003).
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In the tumor environment, hypoxia has many effects on tumor biology. Many of
these effects include: selection of genotypes favoring survival under hypoxia-reoxygenation injury; pro-survival changes in gene expression that suppress apoptosis and
support autophagy; and the anabolic switch in central metabolism (Brown, 2007; Lunt et
al., 2008; Semenza, 2000; Weinmann, Jendrossek, Güner, Goecke, & Belka, 2004).
Hypoxia also enhances receptor tyrosine kinase-mediated signaling, tumor angiogenesis,
vasculogenesis, an epithelial-to-mesenchymal transition, invasiveness, metastasis, as well
as suppressing immune reactivity (Bagnall et al., 2014; Chakraborty, John, & Nag, 2014;
Dewhirst, 2003; Kaidi, Williams, & Paraskeva, 2007; Li & O’Donoghue, 2008; Vaupel
& Mayer, 2005). Due to the continuous effects of the hypoxic environment on tumor
development, hypoxia is implicated in multiple mechanisms in resistance to
chemotherapy (Zeng et al., 2014; Brocato et al., 2014; Kunz & Ibrahim, 2003; Lunt et al.,
2008; Palazon, Goldrath, Nizet, & Johnson, 2014).
Hypoxia Inducible Factor-1
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that
plays a critical role in the cellular response to hypoxia. HIF-1 was discovered by the
identification of a hypoxia response element (HRE; 5′-RCGTG-3′) in the 3′ enhancer of
the gene for erythropoietin (EPO), a hormone that stimulates erythrocyte proliferation
and undergoes hypoxia-induced transcription (Semenza et al., 1991). HIF-1 regulates the
transcription of a broad range of genes that facilitate responses to a hypoxic environment,
including genes regulating angiogenesis, erythropoiesis, cell cycle, metabolism, and
apoptosis. The HIF-1 complex consists of two subunits, HIF-1α and HIF-1β HIF-1, both
of which are basic helix-loop-helix proteins of the PAS family. HIF-1α in seen to
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accumulate under hypoxic conditions whereas HIF-1β is constitutively expressed in both
hypoxic and normoxic conditions. When expressed under hypoxic conditions, HIF-1α is
seen to play a vital role as a mediator for solid tumor expansion including activation of
angiogenic factor VEGF. HIF-1β is the Aryl hydrocarbon Receptor Nuclear Translocator
(ARNT), which is essential for the xenobiotic response (Chai et al., 2014; Unwith, Zhao,
Hennah, & Ma, 2014; Wolff, Jelkmann, Dunst, & Depping, 2013).
Under normoxic conditions, undifferentiated HIF-1 is targeted by an E3 ubiquitin
ligase containing the von Hippel Lindau protein (VLH). The human genome contains
EGL9 (Egg Laying Nine-9) homologues that are named EGLN1, EGLN2, and EGLN3
(also known as PHD2, PHD1, and PHD3 respectively). Prolyl Hydroxylase domaincontaining proteins (PHDs) post-translationally modify HIF-1, allowing interactions with
VHL to occur. All three proteins of PHDs can hydroxylate HIF-1α at one of two proline
sites within the ODD (Pro-402 and Pro-564). VHL is part of a larger protein complex that
includes Elongin-B, Elongin-C, Cul2, RBX1, and an ubiquitin-conjugating enzyme (E2).
This complex, along with ubiquitin-activating enzyme (E1), regularly mediates
ubiquitylation of HIF-1 and its subunits (Ke & Costa, 2006).
In hypoxic conditions, HIF-1α subunits are not recognized by pVHL, this leads to
accumulation of HIF-1α which dimerize with HIF-1β and translocate into the nucleus. In
the nucleus, these proteins act as transcriptional regulators with cofactors such as
CBP/p300 and DNA polymerase II complex to bind to hypoxia-responsive elements
(HREs) and activate transcription of target genes. The understanding of HIF-1α target
genes is well understood, HIF-1α-activated genes include Vascular Endothelial Growth
Factor (VEGF), Glucose Transporter-1 (GLUT1), Lactate Dehydrogenase (LDHA),
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Ertythropoietin (EPO), and Nitric Oxide Synthase (NOS) (He et al., 2014; Zeng et al.,
2014).
HIF-1α and Tumor Cell Metabolism
In a hypoxic environment, the cell relies on anaerobic components of energy
metabolism to survive. Working at a high rate and with a high power output, the cell
enhances its anaerobic glucose metabolism pathways, which in turn inhibit mitochondria
regulation of metabolism. Cytoplasmic presence of undifferentiated HIF-1 and
differentiated HIF-1α is understood to enhance the activity of glucose transporter 1,
hexokinase, phosphoglucose isomerase, aldolase, phosphoglycerate kinase,
phosphoglucomutase, enolase, pyruvate kinase, and lactate dehydrogenase. Essentially,
the presence of HIFs in the cytoplasm up regulates every enzyme responsible for
anaerobic metabolism. This increased cellular rate of glycolysis and decreased presence
and activity of citric acid cycle enzymes is linked with tumor malignancy and can
contribute to tumor metastasis. This is thought to be especially true of the hypoxic
regions present in solid tumors. (Cairns et al., 2011; Kaelin, 2011; Pettersen et al., 2014;
Zeng et al., 2014). A high rate of glucose metabolism is highly regulated in the
stabilization of HIF-1α which activates transcription of glucose transporters and key
glycolytic enzymes such as; lactate dehydrogenase A (LDHA), phosphoglycerate kinase1 (PGK-1), and hexokinase-1 (HK1). Transcription of these components acts to further
facilitate the increase in anaerobic glycolysis and the glycolytic switch (Cairns et al.,
2011; Yasuda, 2008; Zeng et al., 2014).
In normal tissue, approximately 10% of cellular energy is obtained through
anaerobic glycoglysis, whereas mitochondrial aerobic respiration accounts for the other
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90%. In solid tumors, the glycolytic switch increases anaerobic glycolysis contribution to
more than 50%. However, when tumors are introduced to a normoxic environment
mitochondrial function does not increase, this mechanism is suggested to be due to
increased expression of HIF-1α. (Cairns et al., 2011; Racker & Spector, 1981;
WARBURG, 1956; Zeng et al., 2014). Increased pyruvate dehydrogenase activity
mediated through HIF-1α facilitates an increased turnover ratio of pyruvate to lactate.
Furthermore, HIF-1α mediates and increased expression of pyruvate dehydrogenase
kinase 1 (PDK-1) which functions to block the action of pyruvate dehydrogenase.
Pyruvate dehydrogenase is responsible for changing pyruvate to acetyl CoA, which is
then transported to the mitochondria to begin aerobic cellular respiration. Blocking of
pyruvate dehydrogenase along with increased expression of anaerobic metabolic enzymes
serves as a two-fold inhibition of aerobic respiration and requires solid tumor to rely
primarily on glucose metabolism for fuel (Lum et al., 2007) . HIF-1α is not a simple
transcription factor inducer of glycolytic genes, but instead reprograms the fate of
intracellular glucose; this is described as the Warburg effect (Cairns et al., 2011; Kaelin,
2011; Racker & Spector, 1981; WARBURG, 1956).
Growth factor-dependent induction of HIF-1α appears to partially contribute to
the ability of growth factors and oncogenic mutations to the ability of growth factors and
oncogenic mutations in the PI3K/Akt signal transduction pathway to induce a metabolic
conversion to predominantly anaerobic glycolysis (Carmeliet et al., 1998; Lum et al.,
2007; Newton et al., 2010; Palazon, Goldrath, Nizet, & Johnson, 2014). The chronic
inhibition and low activity of the mitochondria is postulated to results in disruption of
normal functioning of the mitochondria. The low-oxygen environment in tumor cells can

25

also result in dysregulation of genes involved in normal mitochondrial function,
especially genes involved in control of apoptosis. Evidence attributes a relationship
between decreased function of the mitochondria to an over-expressed form of
mitochondrial-bound hexokinase which also contributes to high rates of glycolysis
(Faubert et al., 2014; Lum et al., 2007; Mathupala, Ko, & Pedersen, 2009; Sun et al.,
2013; Unwin et al., 2003). A study conducted by Christofk et al., 2008 showed evidence
of this effect could be due to mutations in the Von Hippel-Lindau tumor suppressor gene,
the gene responsible for targeting and ubiquitylation of HIF-1. This further suggesting
HIF-1α may be a key regulator to tumor apoptosis resistance in addition to sustaining
proliferative stimuli.
HIF-1α and the Apc gene
It is well established that the key response to hypoxia is activation of the
transcription factor HIF-1α. However, in the tumor microenvironment there is sufficient
interplay between the HIF-1α regulated gene transcripts and total expression of HIF-1α
(Carmeliet et al., 1998; Ke & Costa, 2006; Newton et al., 2010; Näthke & Rocha, 2011;
Palazon, Goldrath, Nizet, & Johnson, 2014). The Apc gene plays a significant role in
regulation of the fundamental processes that govern normal gut epithelium. It is best
known for control of the Wnt/β-catenin pathway, where it is responsible for the
regulation of β-catenin which thereby regulates that transcriptional activity of T-cell
factor (TCF)/lymphoid-enhancing factor (LEF) transcription factors(Bienz & Clevers,
2000).
Although not extensively investigated, the functional relationship between HIF-1α
and the Wnt/β-catenin pathway has been established in recent investigations. HIF-1α can
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specifically interfere with co-activation of TCF/LEF transcription mediated by β-catenin
and furthermore can bind and regulate NF-κB activity which is theorized to contribute to
chronic inflammation seen in the colon tissue (Bienz & Clevers, 2000; Kaidi et al., 2007;
Sebio et al., 2014). Functional cross-talk has also been reported between HIF-1α and the
Apc gene at the transcriptional level. Newton et al., 2010 reported a consistent direct
transcriptional repression of Apc by HIF-1α. It was seen that HIF-1α bound to a hypoxiaresponsive element, dubbed HRE, in the APC promoter region in the presence of
hypoxia. This relationship was also confirmed in an APC depletion model which showed
an increased HIF-1α expression and activity. The increase of HIF-1α was also determined
to be mediated by NF-κB and was regulated by increased β-catenin levels which were
increased due to the depletion of the Apc gene.
Intracellular induced apoptosis and HIF-1α
In the absence of a trophic factor the phosphatidylinositol-4, 5-bisphosphate 3kinase (PI-3K)/ protein kinase B (PKB) signaling pathway is not activated and the
phosphorylation of Bad does not occur. This allows for Bad to bind with anti-apoptotic
gene B-cell lymphoma 2 (Bcl-2) and prevents the heterodimerization of Bcl-2 with antiapoptotic sister gene B-cell lymphoma-extra large (Bcl-xL) on the mitochondrial
membrane. Absence of this heterodimerization signals for the heterodimerization of Bcl2-associated X protein (Bax) and Bcl-2 homologous antagonist killer (Bak) on the outer
mitochondrial membrane which acts as an ion channel and causes an influx of various
ions across a membrane potential. This ion flux influences the release of cytochrome c
from the mitochondria into the cytoplasmic space. The release of cytochrome c from the
mitochondria initiates the formation of multi-protein complex containing cytochrome c,
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apoptotic protease activating factor 1 (APAF1), and procaspase-9. Formation of this
complex represents the "point of no return" in the apoptosis pathway and cleaves
procaspase-9 to form active cleaved caspase-9 which activates the downstream caspase
cascade and will result in programmed cell death. The release of second mitochondrialderived activator of caspases (SMAC), also known as direct inhibitor of apoptosis protein
(IAP)-binding protein with low pI (DIABLO), is released by the mitochondria to further
stimulate caspase cascades by inhibiting apoptosis inhibitor proteins (IAPs) (Erler et al.,
2004; Wei et al., 2001; Xin & Deng, 2006; Zhang et al., 2004).
Defective apoptosis is frequently associated with malignancies originating from
B-lymphocytes. Bcl-2 family proteins govern the mitochondrial outer membrane
permeabilization (MOMP) in the intrinsic regulation of apoptosis. In the presence of a
trophic factor, PI-3K is activated and leads to the activation of protein kinase B (PKB or
Akt) which hydrolyzes ATP to phosphorylate pro-apoptotic protein Bcl-2-associated
death promoter (Bad). Phosphorylated BAD at this point forms a 14-3-3 heterodimer
which prevents its binding to Bcl-2 which leaves Bcl-2 to form a heterodimer with BclxL. The formation of this dimer does not allow for the formation and opening of Bax/Bak
heterodimer ion channel to promote the release of cytochrome c to the cytoplasm.
Absence of cytochrome c does not allow for the formation of the cytochrome c/APAF1/procaspase-9 multiprotein complex which does not allow for the initiation of apoptosis.
Therefore, apoptosis is actively inhibited through the blocking of this mechanism which
is stimulated by the presence of a trophic factor (Erler et al., 2004; Moreno-Galindo et al.,
2014; Wei et al., 2001; Xin & Deng, 2006; Zhang et al., 2004).
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HIF-1α presents a multi-influential role on the inhibition of intracellular apoptosis
in the tumor microenvironment. Found on chromosome 14q23.2, HIF-1α is actively
expressed in a hypoxic environment (Carmeliet et al., 1998; Erler et al., 2004; Kaidi et
al., 2007; Kunz & Ibrahim, 2003; Poitz et al., 2011; Wolff et al., 2013). Paradoxically,
cell adaptation to hypoxia leads not only to cell proliferation/survival but also to cell
death in some circumstances. Hypoxia has been shown to induce apoptosis, where HIF-1
plays a complex role (Bristow & Hill, 2008; Kaidi et al., 2007; Rouschop et al., 2010;
Zhou et al., 2014). Genetic studies using embryonic stem cells harboring a deletion of
HIF-1α have showed decreased apoptosis compared with wild type cells when challenged
with low oxygen (Carmeliet et al., 1998; Erler et al., 2004). Activation of caspase-3 and
Apaf-1-mediated caspase-9, and the release of cytochrome c, have been reported in
several cell types under hypoxic conditions (Favaro, Lord, Harris, & Buffa, 2011;
McClintock et al., 2002; Pettersen et al., 2014; Rouschop et al., 2010). It has also been
demonstrated that the expression of HIF-1α and HIF-1β significantly correlated with
apoptosis and the pro-apoptotic factors, such as caspase-3, Fas, and Fas ligand (Volm &
Koomägi, 2000). Furthermore, hypoxia depresses anti-apoptotic protein Bcl-2, whereas
the pro-apoptotic protein Bcl-2/adenovirus EIB 19-kDa interacting protein 3 (BNip3) and
its homolog Nip3-like protein X (NIX) were up-regulated in a HIF-dependent manner
(Bruick, 2000; Kunz & Ibrahim, 2003). Some genes involved in cell cycle control, such
as p53 and p21, were also found to be HIF-dependent (Carmeliet et al., 1998; Diab-Assef
et al., 2002; Erler et al., 2004). In addition, p53 has been implicated in regulating
hypoxia-induced apoptosis through induction of apoptosis-related genes such as Bax,
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NOXA, PUMA, and PERP (Bai & Wang, 2014; Kunz & Ibrahim, 2003; Rosado-Berrios,
Vélez, & Zayas, 2011; Weinmann et al., 2004).
In addition to the above classes of genes, HIF-1 also regulated many other target
genes implicated in diverse processes such as adipogenesis (Lin, Lee, Shim, Chun, &
Yun, 2010; Yun, Maecker, Johnson, & Giaccia, 2002), carotid body formation (Favaro et
al., 2011; Kline, Peng, Manalo, Semenza, & Prabhakar, 2002), B lymphocyte
development, and immune reactions (El Awad et al., 2000; Hellwig-Bürgel, Rutkowski,
Metzen, Fandrey, & Jelkmann, 1999; Rosado-Berrios et al., 2011). Although there are
some studies showing a role of HIF-2α in the VEGF induction (Duan, Zhang-Benoit, &
Fong, 2005; Xue & Shah, 2013; Xue et al., 2012), no direct target genes have yet been
identified for HIF-2α or HIF-3α. However, a recent study using a genetic “knock-in”
strategy has shown that targeted replacement of HIF-1α with HIF-2α results in expanded
expression of HIF-2α-specific target genes, the most significant find being Oct-4, a
transcription factor essential for maintaining stem cell pluripotency (Covello et al., 2006).
2.5 2-benzoyl-3-phenyl 6,7-dichloroquinoxaline 1,4-dioxide
Quinoxaline di-N-oxides (QdNOs) were approved in the late 1960's for use as
feed additives in livestock farming to promote animal growth and as an effort to replace
banned therapeutic antibiotics, penicillin, and tetracyclines (Diab-Assef et al., 2002; H.
U. Gali-Muhtasib et al., 2005). Approval of QdNOs for use was due to the large body of
evidence showing that quinoxaline antibiotics are inhibitors of DNA synthesis and had
increased effectiveness in anaerobic conditions. The structural design of QdNOs is the
key to the increased effectiveness of DNA synthesis inhibition in these types of
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antibiotics. In the presence of an electron rich environment, a free radical intermediate is
created by the transfer of an electron from this electron rich environment to the electronpoor nitrogen centers of the 1,4-di-N-oxide moiety. In a hypoxic environment, this
transfer is more likely to occur due to the highly reducing conditions of hypoxic cells,
leading to hypoxic cells acting as a targeting element to cytotoxicity of these compounds
(Diab-Assef et al., 2002; El-Khatib et al., 2010; H Gali-Muhtasib et al., 2000; H. U. GaliMuhtasib et al., 2005; Hala Gali-Muhtasib et al., 2004; Ganley et al., 2001).

Figure 2.1 2-benzoyl-3-phenyl 6,7-dichloroquinoxaline 1,4-dioxide.

DCQ administration has shown promising evidence of tumor specific apoptosis
and decreased proliferation through interactions with the HIF-1α pathway. Preliminary
research from the American University of Beirut has shown tumor specific cytotoxicity
mechanisms of quinoxaline 1,4-dioxides (QdNOs) cultured under hypoxic conditions.
The QdNOs were found to possess a 50- to 100- fold greater cytotoxicity to human T-84
colorectal cells cultured under hypoxia compared to an oxic environment. It was reported
that the hypoxia cytotoxicity ratio (HCR), the ratio of equitoxic concentrations of the
drug under aerobic/anoxic condition, was highly structure related and dependent on the
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nature of the substituents' on the QdNO heterocycle. The most cytotoxic, 2-benzoyl-3phenyl-6,7-dichloro derivative of the quinoxaline 1,4-dioxide was potent at a dose of
1μM with an HCR of 100 and significantly reduced the levels of HIF-1α transcript and
protein. It was further hypothesized that the C-6 and C-7-chlorine of DCQ might play a
significant role in the selective hypoxic cytotoxicity of the drug (Diab-Assef et al., 2002;
H Gali-Muhtasib et al., 2000).
In a supplemental study, DCQ was tested for IC50 and compared to QdNOs; AMQ
and BPQ. It was seen that the IC50 of AMQ, BPQ, and DCQ were 100, 20, and 1μM,
respectively. Thus, the concentration of DCQ to induce 50% growth inhibition was 20fold lower than that of BPQ and 100-fold lower than that of AMQ. It was also seen that
these compounds were not cytotoxic to normal intestinal IEC-6 or Moe K cells at their
IC50 concentration (Diab-Assef et al., 2002; H. U. Gali-Muhtasib et al., 2005). To
investigate the effect of DCQ on tumor cells, H. U. Gali-Muhtasib et al., 2005 exposed
cultured T-84 human colon carcinoma cells to 1μM DCQ for a 48 hour period. Upon
treatment with DCQ, the accumulation of sub-G1 peak of hypo-diploid cells was evident
and was seen in more than 35% of total cells. TUNEL assay of cultured cells also showed
60% of cultured cells were positive for dsDNA strand breaks compared to 35% for BPQ
and 10% for AMQ. These findings suggested DCQ works by targeting the tumor
microenvironment to induce anti-proliferative effects specifically in the tumor cells
through an increase in cell apoptosis pathways (Diab-Assef et al., 2002; H. U. GaliMuhtasib et al., 2005). It was also seen that DCQ significantly increased pro-apoptotic
protein Bax and decreased anti-apoptotic protein Bcl-2 in T-84 cells. This indicating
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activation of mitochondrial induced apoptosis of the cell as a specific mechanism of
action leading to tumor cell apoptosis.
DNA damage, in particular dsDNA breaks, imposes a threat to the survival of
cells if left unrepaired. At the early stages of the DNA damage response, Ataxia
telangiectasia mutated kinase (ATM) is autophosphorylated on Ser1981 as a response to
the presence of dsDNA breaks. ATM activation, in turn, proceeds to phosphorylate p53,
thereby blocking its interaction with E3 ubiquitin-protein ligase (MDM2), causing its
stabilization. Stabilized p53 stimulates the expression of cyclin-dependent kinase
inhibitor p21. Through its various interactions, p21 inhibits G1/S and G2/M transitions
which lead to cell cycle arrest and repair or apoptosis. Thus, increased expression of p53
levels that are paralleled by increased p-ATM and p21 are due to this pathway activation
and lead to cell-cycle arrest, repair, and cell death. Malignant tumor cells harbor a
defective p53 and are resistant to this pathway, this favors their clonal outgrowth and
contributes to the resistance of normal cell cycle responses to DNA damage, a cause of
chemotherapy and radiation resistance (Kaluzová, Kaluz, Lerman, & Stanbridge, 2004;
Lakin & Jackson, 1999; Vilenchik & Knudson, 2003).
In an attempt to investigate the specific cytotoxic mechanisms of DCQ, El-Khatib
et al., 2010 treated cultured HCT116 (p53+/+), HCT116 (p53-/-), and HCT116 (p21-/-) cells
to 0, 5, and 10μM DCQ in DMSO media for 6, 12, and 24 hours under normoxic and
hypoxic conditions. p53 protein increased in response to DCQ in all three cell lines with
the exception of the p53+/+ cells exposed to hypoxia, the same pattern was also seen for
p21 protein expression. Caspase-2 expression was increased in p53+/+ cells and was
further increased by 8-10 fold under hypoxia. In p53-/- showed no increase in caspase-2
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and a decreased expression was seen in p21-/- cells. Although no direct interaction
between p53 and caspase-2 has been observed, it is theorized that a functional connection
between these two proteins is essential for the initiation of drug-induced apoptosis (Erler
et al., 2004; Lakin & Jackson, 1999; Seth, Yang, Kaushal, Shah, & Kaushal, 2005).
Overall, the apoptotic effects of DCQ in p53+/+ cells correlated with an increase in the
pro-apoptotic caspase-2 protein, inhibition of pro-survival protein p53-induced protein
with a death domain (PIDD-C), and increase in p-ATM expression.
The p21 gene is transcriptionally activated by p53 and is responsible for the p53dependent checkpoint which induces cell cycle arrest in the event of DNA damage.
Enforced p21 expression is known to result in a consistent, but partial, protection of cells
from apoptosis (Bunz et al., 1998; Kaluzová et al., 2004; Lakin & Jackson, 1999; et al.,
2005). A significant increase was observed in both p53+/+ and p53-/- cells when treated
with DCQ in a hypoxic environment, this suggesting that p21 activation is independent of
p53 in the case of DCQ. The decrease in the expression of pro-survival PIDD-C protein
coupled with the increase in pro-apoptotic caspase-2 in p53+/+ cells appeared to have
committed the cells to apoptosis. Interestingly, in p53-/- and p21-/- cells, apoptotic cell
death occurred independent of caspase-2 activation and/or PIDD-C down-regulation (ElKhatib et al., 2010). This suggesting that the apoptotic mechanism involved in the tumor
selective cell death of DCQ is independent of p53 and p21 proteins, further suggesting
the involvement of other apoptotic mechanisms.
Administration of DCQ in both tumor cell cultures and healthy epithelial cells at
concentrations of 5μM and 10μM show promising results to tumor specific induction of
apoptosis via HIF-1α pathway and intracellular apoptosis (El-Khatib et al., 2010; H. U.
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Gali-Muhtasib et al., 2005; Ghattass et al., 2014). While there is evidence of direct
effectiveness of DCQ in cell cultures and a suggested safe concentration of 17mg/kg
dosage, there is still an incomplete understanding of the effectiveness, safety, and direct
mechanisms of action that account for the tumor specific targeting of DCQ. The overall
goal of this proposal is to determine clinical effectiveness of DCQ in inducing apoptosis
of colorectal tumor cells and systemic safety of the 17mg/kg dosage in an implant and
genetic model of colorectal cancer. Our central hypothesis is that DCQ administered at a
concentration of 17mg/kg will be effective at reducing tumor size and burden in both
models of colorectal cancer and continue to work through the HIF-1α pathway and
induce mitochondrial apoptosis without showing signs of systemic toxicity.
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CHAPTER 3
NOVEL DRUG 2-BENZOYL-3-PHENYL 6,7-DICHLOROQUINOXALINE 1,4-DIOXIDE INDUCES
COLON CANCER CELL APOPTOSIS THROUGH HIF-1[ALPHA] PATHWAY1

Alexander T. Sougiannis1, Arpit Saxena1, Kamaljeet Kaur1, Hala U. Gali-Muhtasib1,
Makhluf J. Haddadin1, Raja Fayad*1. To be submitted to Biochimica et biophysica acta
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3.1 Abstract
Recent developments in the field of cancer genomics have shown transcription factor
HIF-1α as a major player in the survival and proliferation of colorectal tumors. Presence
of hypoxic areas in tumors facilitate the differentiation and nuclear translocation of HIF1α which leads to transcription of hypoxic genes causing vascularization and metastasis
of tumors. Hypoxia targeted drug engineering has led to significant advancements in
cancer treatments as a method of directly utilizing the hypoxic regions against the tumor.
Novel drug DCQ (2-benzoyl-3-phenyl 6,7-dichloroquinoxaline 1,4-dioxide) has shown
promising anti-tumor results in-vitro and in-vivo. The purpose of this study was to utilize
a tumor xenograft and genetic mouse model of colorectal cancer to investigate the safety,
clinical effectiveness, and mechanism of action of DCQ. Methods: 10 week old Balb/c
mice were injected subcutaneously with 2 million CT-26 cells and were monitored for
tumor growth over 14 days before receiving treatment. Apcmin/+ mice were clinically
evaluated from 8 weeks of age and began treatments at 16 weeks of age. DCQ treatment
given at a 17mg/kg dose and 100μL DMSO injection as control. Injections were given biweekly over a four week period. At sacrifice, all tissues were extracted for histological
and protein analysis. Results: DCQ caused significant decrease in tumor weight (p<0.05)
and final tumor area (p<0.05) in Balb/c mice at time of sacrifice than control. Apcmin/+
mice showed significantly lower clinical score after 1 week of therapy along with
decreased large tumor size (p<0.05) and number (p<0.05). Histological analysis showed
increased total apoptotic area (p<0.05) in tumor tissue sections and tumor specific
apoptosis in colon tissue in both models. Western blot analysis of Balb/c tumors and
Apcmin/+ colon tumors showed a decreased nuclear expression of HIF-1α (p<0.05) and
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increased expression of pro-apoptotic genes dephosphorylated-Bad (p<0.001), cleaved
caspase-9 (p<0.05), and Bax (p<0.05) paralleled with a decrease in anti-apoptotic Bcl-2
gene (p<0.05). Conclusions: DCQ induces tumor apoptosis involving down regulation of
HIF-1α and increased intracellular apoptosis in Balb/c mice and Apcmin/+ mice. Novel
drug DCQ may potentially have use as a chemotherapeutic agent to reduce the pathology
of sporadic intestinal and colorectal cancers.
KEYWORDS: Cancer, Colon, DCQ, Drug
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3.2 Introduction
In 2012 the WHO reported cancer as the leading cause of death worldwide
accounting for nearly 8.2 million deaths. In the United States, cancer related deaths were
reported as second highest behind heart disease (Torre et al., 2015). Colorectal cancer is
the second most prevalent cancer in both men and women in the United States in terms of
incidence and death rates. The American Cancer Society estimates approximately 51,000
Americans will die of colon cancer and nearly 150,000 new cases will be diagnosed in
2014 (Siegel, DeSantis, & Jemal, 2014). The financial burden of colorectal cancer has
had a large impact on the current health care system. In 2010, the direct cost of colorectal
cancer was estimated to be $12.2 billion dollars, $10.7 being due to lost productivity and
premature death (Siegel et al., 2014; Torre et al., 2015). Thus, a need does exist for the
development of safer and more effective therapeutic treatments in order to prevent loss of
life from ineffective treatments.
The initial incidence of hypoxia in the tumor environment arises because of
oxygen diffusion limitations in avascular primary tumors (Lunt, Chaudary, & Hill, 2008;
Mathonnet et al., 2014; Ryan, Lo, & Johnson, 1998; Zeng, Liu, Pan, Singh, & Wei,
2014). As a result of increased hypoxia in the tumor environment, the tumor
microvasculature proliferates and serves to benefit tumor growth and metastasis. Normal
responses to hypoxia typically see increased microvasculature proliferation in the tissue
but with eventual compensation by the body through increased red blood cell count and
increased oxygen carrying capacity of the blood (Lunt et al., 2008; Yasuda, 2008). In the
tumor environment, the increased microvasculature proliferation in the tumor tissue is
highly abnormal and often fails to correct for the oxygen deficit. This persistent hypoxia
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leads to spatial disorganization of the tumor vascular networks and eventually leads to
intercapillary distances that are beyond the diffusion range of oxygen (~200μm)
(Brocato, Chervona, & Costa, 2014; Kunz & Ibrahim, 2003).
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that
plays a critical role in the cellular response to hypoxia. HIF-1 was discovered by the
identification of a hypoxia response element (HRE; 5′-RCGTG-3′) in the 3′ enhancer of
the gene for erythropoietin (EPO), a hormone that stimulates erythrocyte proliferation
and undergoes hypoxia-induced transcription (Semenza, Nejfelt, Chi, & Antonarakis,
1991). HIF-1 regulates the transcription of a broad range of genes that facilitate responses
to a hypoxic environment, including genes regulating angiogenesis, erythropoiesis, cell
cycle, metabolism, and apoptosis. The HIF-1 complex consists of two subunits, HIF-1α
and HIF-1β, both of which are basic helix-loop-helix proteins of the PAS family. HIF-1α
is thought to accumulate under hypoxic conditions whereas HIF-1β is constitutively
expressed in both hypoxic and normoxic conditions. When expressed under hypoxic
conditions, HIF-1α plays a vital role as a mediator for solid tumor expansion including
activation of angiogenic factor VEGF. HIF-1β is the Aryl hydrocarbon Receptor Nuclear
Translocator (ARNT), which is essential for the xenobiotic response (Wolff et al., 2013).
Under normoxic conditions, undifferentiated HIF-1 is targeted by an E3 ubiquitin ligase
containing the von Hippel Lindau protein (VLH). The human genome contains EGL9
(Egg Laying Nine-9) homologues that are named EGLN1, EGLN2, and EGLN3 (also
known as PHD2, PHD1, and PHD3 respectively). Prolyl Hydroxilase domain- containing
proteins (PHDs) post-translationally modify HIF-1, allowing interactions with VHL to
occur. All three proteins of PHDs can hydroxylate HIF-1α at one of two proline sites
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within the ODD (Pro-402 and Pro-564). VHL is part of a larger protein complex that
includes Elongin-B, Elongin-C, Cul2, RBX1, and an ubiquitin-conjugating enzyme (E2).
This complex, along with ubiquitin-activating enzyme (E1), regularly mediates
ubiquitylation of HIF-1 and its subunits (Ke & Costa, 2006).
In hypoxic conditions, HIF-1α subunits are not recognized by pVHL, this
condition leads to accumulation of HIF-1α which dimerize with HIF-1β and translocate
into the nucleus. These proteins in the nucleus act as transcriptional regulators with
cofactors such as CBP/p300 and DNA polymerase II complex to bind to hypoxiaresponsive elements (HREs) and activate transcription of target genes. The functioning of
HIF-1α target genes is well understood. HIF-1α-activated genes include Vascular
Endothelial Growth Factor (VEGF), Glucose Transporter-1 (GLUT1), Lactate
Dehydrogenase (LDHA), Ertythropoietin (EPO), and Nitric Oxide Synthase (NOS) (He,
Jiang, Zhang, & Wu, 2014; Zeng et al., 2014). Although not extensively investigated, the
functional relationship between HIF-1α and the Wnt/β-catenin pathway has been
established in recent investigations. HIF-1α can specifically interfere with co-activation
of TCF/LEF transcription mediated by β-catenin and furthermore can bind and regulate
NF-κB activity which is theorized to contribute to chronic inflammation seen in the colon
tissue (Bienz & Clevers, 2000; Kaidi et al., 2007; Sebio et al., 2014). Functional crosstalk has also been reported between HIF-1α and the Apc gene at the transcriptional level.
Newton et al., 2010 reported a consistent direct transcriptional repression of Apc by HIF1α. It was seen that HIF-1α bound to a hypoxia-responsive element, dubbed HRE, in the
APC promoter region in the presence of hypoxia. This relationship was also confirmed in
an APC depletion model which showed an increased HIF-1α expression and activity. The
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increase of HIF-1α was also determined to be mediated by NF-κB and was regulated by
increased β-catenin levels which were increased due to the depletion of the Apc gene.
Quinoxaline di-N-oxides (QdNOs) were approved in the late 1960's for use as
feed additives in livestock farming to promote animal growth and as an effort to replace
banned therapeutic antibiotics, penicillin, and tetracyclines (Diab-Assef, Haddadin,
Yared, Assaad, & Gali-Muhtasib, 2002; Gali-Muhtasib, Diab-Assaf, & Haddadin, 2005).
Approval of QdNOs for use was due to the large body of evidence showing that
quinoxaline antibiotics are inhibitors of DNA synthesis and had increased effectiveness
in anaerobic conditions. The structural design of QdNOs is the key to the increased
effectiveness of DNA synthesis inhibition in these types of antibiotics. In the presence of
an electron rich environment, a free radical intermediate is created by the transfer of an
electron from this electron rich environment to the electron-poor nitrogen centers of the
1,4-di-N-oxide moiety. In a hypoxic environment, this transfer is more likely to occur due
to the highly reducing conditions of hypoxic cells, leading to hypoxic cells acting as a
targeting element to cytotoxicity of these compounds (Diab-Assef, Haddadin, Yared,
Assaad, & Gali-Muhtasib, 2002; H. U. Gali-Muhtasib, Diab-Assaf, & Haddadin, 2005).
Administration of quinoxaline di-N-oxides to tumor cultures has shown promising
evidence of tumor specific apoptosis and decreased proliferation through interactions
with the HIF-1α pathway. Preliminary research from the American University of Beirut
has shown tumor specific cytotoxicity mechanisms of quinoxaline 1,4-dioxides (QdNOs)
cultured under hypoxic conditions. The QdNOs were found to possess a 50- to 100- fold
greater cytotoxicity to human T-84 colorectal cells cultured under hypoxia compared to
an oxic environment. Diab-Assef et. al., 2002 reported that the hypoxia cytotoxicity ratio
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(HCR), the ratio of equitoxic concentrations of the drug under aerobic/anoxic condition,
was highly structure related and dependent on the nature of the substituents' on the QdNO
heterocycle. The most cytotoxic, 2-benzoyl-3-phenyl-6,7-dichloro derivative of the
quinoxaline 1,4-dioxide, or DCQ, was potent at a dose of 1μM with an HCR of 100 and
significantly reduced the levels of HIF-1α transcript and protein. Others have further
hypothesized that the C-6 and C-7-chlorine of DCQ might play a significant role in the
selective hypoxic cytotoxicity of the drug (Diab-Assef et al., 2002; H Gali-Muhtasib et
al., 2000). While there is evidence of direct effectiveness of DCQ in cell cultures and a
suggested maximal tolerated dose of 17 mg/kg, incomplete understanding of the in-vivo
effectiveness still exist, as does the overall safety, and direct mechanisms of action that
account for the tumor specific targeting of DCQ. The goal of this study is to determine
clinical effectiveness of DCQ in inducing apoptosis of colorectal tumor cells and
systemic safety of the 17 mg/kg dosage in a xenograft and genetic model of colorectal
cancer. We hypothesized that DCQ administered at a concentration of 17 mg/kg is
effective at reducing tumor burden in both models of colorectal cancer and reduce HIF1α expression along with up-regulated tumor specific intracellular induced apoptosis
without showing signs of healthy tissue toxicity.
3.3 Methods
Animals
Sixteen female Balb/c mice and ten Apcmin/+ mice were bred and housed at the
Arnold School of Public Health animal facility at the University of South Carolina. Mice
were grouped housed, given access to food and water ad libitum, and kept on a 12-hour
light-dark cycle. The study was approved by the Institutional Animal Care and Use
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Committee at the University of South Carolina and was carried out in compliance with
the Guide for Care and Use of Laboratory Animals (National Institutes of Health,
Bethesda, MD). The study used two separate animal models to investigate both an
implant model of colorectal cancer and a genetic model of sporadic intestinal and
colorectal cancer. DCQ treatment was designed to model an intense cycle of single agent
chemotherapy at a progressed stage of colorectal cancer.
Experimental Design: Balb/c Xenograft mice
The study designed did incorporate two separate animal models to investigate
both an implant model of colorectal cancer and a genetic model of sporadic intestinal and
colorectal cancer. At 10 weeks of age, Balb/c mice were randomly assigned (n=8/group)
to a DMSO control group or a DCQ treatment group. Mice in each group were injected
sub-dermally (s.d.) with 2 x 106 CT-26 cells into the subcutaneous area of the right flank,
in incomplete media, and allowed tumors to grow for 2 weeks before receiving 4 weeks
of bi-weekly treatments (Figure 1A). Mice weight was determined daily, and the date of
death was recorded. Changes in tumor size were monitored bi-weekly by measurement of
tumor size (length and width) with a caliper device.
Experimental Design: Apcmin/+ mice
At 8 weeks of age, Apcmin/+ mice were assigned (n=5/group) to a DMSO control
group or a DCQ treatment group and began receiving treatments at 16 weeks of age.
Mice were given DCQ at a 17 mg/kg dosage dissolved in 100 μL DMSO as a treatment
or 100 μL DMSO as control which were administered intraperitoneally (i.p.), twice per
week for 4 weeks (Figure 1B). Toxicity studies by the American University of Beirut
have shown that 17 mg/kg in 100 μL DMSO is a tolerated dosage based on mice behavior
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and body weight. Clinical score was kept for Apcmin/+ mice from 8 weeks of age through
20 weeks of age, and clinical scores were determined based on the predetermined
guidelines of the Integrated Immunology of Inflammation and Cancer lab (Table 1).
Tissue Collection
Balb/c mice treated with DMSO or DCQ were sacrificed after 4 weeks of therapy.
Apcmin/+ mice treated with DMSO were sacrificed after 4 weeks of therapy as well.
Apcmin/+ mice treated with DCQ were sacrificed after 5 weeks of therapy due to
continually improved health. At the time of sacrifice, mice were first injected with 1mg
of Bromodeoxyuridine (BrdU) dissolved in sterile PBS, mice then underwent DEXA scan
and were anesthetized 2 hours (hr) later with an isofluorane-oxygen gas mixture and
sacrificed by cervical dislocation. The colon was removed and flushed with PBS
containing 5000 IU/mL and 5000 IU/mL penicillin and streptomycin (CELLGRO),
respectively. From Apcmin/+ mice, two 2 mm2 sections of the descending colon were
dissected and stored at −80°C for Western blot analysis and at 37 °C, 5% CO2 with
overnight incubation for tissue culture. A single tumor containing section of colon was
fixed in 10% formalin (AZER SCIENTIFIC) for a day then embedded in paraffin wax for
immunohistochemistry staining. Remaining sections of all tissues were snap-frozen in
dry ice, and stored in -80 0C until further analysis (Saxena et al., 2014). Tissues analyzed
for HIF-1α, especially tumor xenografts, were excised and frozen or stored in formalin, in
under 1minute (min) due to the rapid degradation of HIF-1α in a normoxic environment
(Lin et al., 2006).
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Tumor quantification.
Formalin-fixed intestinal sections from all animals were rinsed in deionized
water, briefly stained in 0.1 % methylene blue, and counted by the same investigator who
was blinded to the treatments. Tumors were counted under a dissecting microscope and
were categorized according to size (>2 mm, 1–2 mm, and <1 mm).
Western Blot Analysis
Briefly, tumor xenografts, small intestine tumors, and colon tumors were
homogenized using the Nuclear extraction kit (ab113474) from Abnova to separate
cytoplasmic and nuclear proteins. Protein concentration was determined by the Bradford
method (Bradford, 1976). Crude homogenates (10-50μg) were separated on 10-15 %
polyacrylamide gels by SDS-PAGE gel electrophoresis. Gels were transferred to
nitrocellulose membranes in cold transfer buffer over a 3 hour period. Equal protein
loading of the gels was assessed by ponceau staining. Membranes were then blocked in 5
% milk-PBST for one hour at room temperature. Primary antibodies for Hypoxia
Inducible Factor-1α (HIF-1α; Abnova) in the nucleus, and cytoplasmic cleaved caspase9, dephosphorylated-Bad (d-Bad), Bax, and Bcl-2 were incubated at 1:500 to 1:1000
dilutions in 5 % milk-PBST overnight at 4 0C. HIF-1α was incubated for 2.5 hours at
room temperature. Secondary anti-rabbit IgG conjugated antibodies were incubated with
membranes at a 1:2000 dilution in 5 % milk-PBST for 75 (min) at room temperature. All
antibodies were purchased from cell signaling unless otherwise stated. Enhanced
chemiluminescence was used to visualize the antibody-antigen interaction and developed
by the SYNGENE G:BOX Chemi XX6. Digitally developed blots were analyzed by
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measuring the integrated optical density (IOD) of each band using digital imaging
software (GeneTools from Syngene, Cambridge, UK).
Colon Histopathology
To analyze colon histopathology, tumor containing sections of the descending
colon were stained with hematoxylin and eosin stains. Tumor containing sections of the
descending colon represent advanced stage tumors (Saxena et al., 2014). Briefly, tissues
were sectioned at 5μm thickness and deparaffinized by standard procedure using xylene
and gradation of ethanol. Sections were then washed for 5 min in dH2O, stained with
filtered hematoxylin for 5min, then again washed 6x5 min in dH2O. Sections were
washed in acid alcohol mix (160 mL 100 % EtOH, 1 mL acetic acid, and volumed to 200
mL with dH2O) for 6 dips then again washed in dH2O for 4 dips. Sections were then
washed in Ammonia H2O (0.6 mL Ammonium OH volumed to 200 mL with dH2O) for 6
dips and then again washed in dH2O for 10 min. The sections were then stained with
Eosin for 3min and dehydrated in the following alcohol progression; 1x2 min 70 %
EtOH, 1x2 min 95 % EtOH, 2x3 min 100 % EtOH, and 2x5 min xylene. Slides were then
air dried overnight and mounted for viewing with mounting media. Digital photographs
were taken from each section at a 40x and 20x magnification with a Nikon E600
Widefield Epifluorescence and Darkfield Microscopy System at the University of South
Carolina School of Medicine.
Apoptosis Detection by TUNEL Assay
Terminal deoxynucleaotidyl transferase (TdT)-mediated dUTP-biotin nick-end
labeling (TUNEL) technique was used as per manufacturer instruction (R&D systems) to
detect DNA strand breaks in situ. Briefly, tumor xenografts from Balb/c mice and colon
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tumors from Apcmin/+ mice were sectioned at 5 μm thickness and deparaffinized by
standard procedure using xylene and gradation of ethanol. Negative controls were
performed by substituting PBS for TdT enzyme, which exhibited no immunostaining.
Enumeration of apoptotic nuclei was made on slides of sections from each mouse using a
digital photographs taken at 4x and 20x magnification with a Nikon E600 Widefield
Epifluorescence and Darkfield Microscopy System at the University of South Carolina
School of Medicine. All nuclei counted showing a brown labeling. The incidence of
apoptotic nuclei was given a percentage of total area of entire tumors in tumor xenografts
(total apoptotic area) and counted within the tumor in the case of colon tumors from
Apcmin/+ mice. Staining was performed in three separate experiments and counting was
performed by the same investigator who was blinded to the treatments. Reliability of
counting was obtained by calculating the coefficient of variance between each of the
three data sets and was determined to be less than 10%.
Cell Proliferation by BrdU Assay
Immunohistochemistry was performed to detect proliferating cells marked with
Bromodeoxyuridine by BrdU IN-SITU Detection Kit from BD Pharmingen (550803).
Briefly, tumor xenografts from Balb/c mice and colon tumors from Apcmin/+ mice were
sectioned at 5μm thickness and deparaffinized by standard procedure using xylene and
gradation of ethanol. Negative controls were performed by substituting PBS for antiBrdU primary antibody incubation, which exhibited no immunostaining. Enumeration of
positively marked cells was made on slides of sections from each mouse using digital
photographs taken at 4x and 20x magnification with a Nikon E600 Widefield
Epifluorescence and Darkfield Microscopy System at the University of South Carolina
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School of Medicine. Positive cells were indicated by a brown labeling. The incidence of
proliferating cells was given a percentage of total area of entire tumors in tumor
xenografts (total proliferative area) and counted in the case of colon tumors. Staining was
performed in three separate experiments and counting was performed by the same
investigator who was blinded to the treatments. Reliability of counting was obtained by
calculating the coefficient of variance between each of the three quantified data sets and
was determined to be less than 7%.
Statistical Analysis
Two-way analysis of variance (ANOVA), Two-way repeated measure ANOVA
and One-way ANOVA with Tukey post-hoc analysis was used to analyze within group
data. Balb/c mice and Apcmin/+ mice were not compared. Western blot and histology data
statistical analysis was calculated by Student's t-test using SigmaStat version 3.5 (Systat
Software Inc., Richmond, CA). Results are reported as means ± standard error of the
mean. Significance was set with an alpha value of p < 0.05.
3.4 Results
DCQ reduces tumor xenograft weight and area after 4 weeks of treatment in Balb/c mice.
We investigated the effectiveness of a 17 mg/kg DCQ dosage given semiweekly
to Balb/c mice with CT-26 tumor xenografts. Figure 1A shows photographs of DMSO
and DCQ treated mice at the beginning and after the 4 week treatment period After 4
weeks of treatment, DCQ treated mice showed decreased tumor weight (p < 0.05) and
area (p < 0.05) compared to DMSO treated mice (Figure 1 B-C). This data is consistent
with the results obtained by where tumor volume was shown to be lower in DCQ treated
Balb/c mice with MDA-MB-231 tumor xenografts (Ghattass, K, et. al., 2014).
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DCQ induces tumor apoptosis and decreases proliferation.
Two important hallmarks of cancer that contribute to the malignancy of tumor
development is the ability for the cancerous mass to resist apoptotic signaling and sustain
proliferative signaling. An ideal chemotherapeutic drug would have the ability to induce
both tumor cell apoptosis and block the tumor cells’ ability to proliferate. To evaluate the
effect of DCQ on inducing tumor apoptosis, a standard TUNEL staining assay was
performed on excised tumor xenograft sections (Figure 2a). Balb/c mice treated with
DCQ showed a significantly greater percent apoptotic area within the tumor mass (p <
0.05) compared to DMSO treated mice (Figure 2b). To assess the ability of DCQ to block
the sustained proliferation of tumor masses, a standard BrdU staining assay was
performed on tumor xenograft sections (Figure 3). Balb/c mice treated with DCQ also
showed a decreased percent proliferative area within the tumor mass (p < 0.05) compared
to DMSO treated mice (Figure 3b).
DCQ decreases nuclear expression of HIF-1α transcription protein.
The structural design of DCQ is the key to the increased effectiveness of DNA
synthesis inhibition. In the presence of an electron rich environment, a free radical
intermediate is created by the transfer of an electron from this electron rich environment
to the electron-poor nitrogen centers of the 1,4-di-N-oxide moiety. In a hypoxic
environment, this transfer is more likely to occur due to the highly reducing conditions of
hypoxic cells, leading to hypoxic cells acting as a targeting element to cytotoxicity of the
compound, (Ke & Costa., 2006) this is especially true in models of colorectal cancer
where tumors thrive in a low oxygen environment. To assess the extent of hypoxic
signaling within the tumor xenografts, nuclear HIF-1α expression was evaluated via
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Western blot analysis (Figure 4a). DCQ treated Balb/c mice decreased both HIF-1α
(p<0.05) and undifferentiated HIF-1 (p<0.05) protein levels within the nucleus of the
tumor cells (Figure 4b,c).
DCQ induces tumor cell apoptosis through intracellular death pathway.
Gali-Muhtasib et al., 2005 showed DCQ was the most effective QdNO to induce
tumor cell apoptosis in cultured T-84 human carcinoma cells and did so by increasing
intracellular pro-apoptotic protein Bax while decreasing anti-apoptotic protein Bcl-2. To
confirm activation of this pathway, we mapped the pro-apoptotic and anti-apoptotic
markers of the intracellular death pathway in the excised tumor xenografts (Figure 5a) via
Western blot analysis. In this circumstance, DCQ increased pro-apoptotic genes cleaved
caspase-9 (p<0.05), dephosphorylated-Bad (p<0.001), and Bax (p<0.05) after 4 weeks of
treatment (Figure 5b, c, d). DCQ decreased anti-apoptotic protein Bcl-2 (p<0.05), and
this treatment effectively reducing the ratio of Bcl-2 to Bax (Figure 5e). Loading of
equivalent amounts of protein for all samples was confirmed by ponceau stain. On the
basis of quantification of the data by scanning densiometry, DCQ was found to increase
intracellular death pathway signaling.
4 weeks DCQ treatment at 17mg/kg may not induce liver, kidney, or brain apoptosis.
In an effort to test the safety of the determined maximal tolerated dose of
17mg/kg, brain, liver, and kidney were excised from mice at the time of sacrifice and
stained for apoptotic activity via standard TUNEL staining assay. Representative photos
of DMSO and DCQ treated mice in Figure 6 show no positive indications of apoptotic
activity in either mouse. These results indicate that DCQ treatment at 17mg/kg may not
induce toxicity to these organs during the 4 week treatment period.
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Improved clinical score after 4 weeks DCQ treatment in 16 week old Apcmin/+ mice
After confirming the effectiveness and safety of the 17 mg/kg dosage in the tumor
xenograft model, the effectiveness and safety of the same dosage in a genetic model of
intestinal/colorectal cancer was determined. Apcmin/+ mice began semiweekly clinical
evaluation (Table 1) at 8 weeks of age and began semiweekly DCQ or DMSO treatments
at 16 weeks of age which lasted 4 weeks. Figure 8a represents the clinical score tallied
across the entire study, statistical significance was only calculated from the beginning of
the treatment period, 16 weeks of age. Although the breeding group used for the DCQ
treatment showed a higher clinical score prior to treatment and had a significantly higher
score at the first treatment visit (p < 0.05); by week 17, mice receiving DCQ treatment
showed a continuous downward progression in clinical score which tallied to be
significantly less than the DMSO treated mice (p < 0.05) at all but one time point (week
16.5) throughout the treatment period.. Decreased clinical score was attributed to a
decreased scoring in diarrhea and fecal hemoccult (data not shown). At 20 weeks of age,
DCQ treated mice were determined to still be “healthy” by the Arnold School of Public
Health animal facility staff and were given another week of treatment before sacrifice.
DCQ treated mice were all sacrificed at 21 weeks of age. Clinical score data for DMSO
treated mice was only tallied to 19 weeks of age due to decreased health of the animals
and many needing to be sacrificed before reaching the 20 week threshold. The data point
at 19 weeks of age for the DMSO treated group represents the last point which all mice
within the DMSO treatment group clinical score was tallied. One-way ANOVA of
Apcmin/+ mice within the DCQ treatment group revealed a progressive increase in clinical
score relative to time from 8 weeks to 16 weeks of age (p < 0.001), prior to DCQ
administration. From 16 weeks of age to sacrifice, during the DCQ treatment period,
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mice showed significant decrease (p < 0.001) in clinical score relative to time which
indicates a change in clinical score was induced by DCQ treatment.
DCQ decreases intestinal tumor count and size
To investigate the overall effectiveness of DCQ, we excised the entire small
intestine and colon and counted tumors after staining with 0.1% methylene blue. No
morphological differences in the colon were observed between the DMSO and DCQ
treated mice (Figure 8a). However, DCQ treated mice did show a decreased total tumor
number (p < 0.001) and large tumor size (p < 0.001) compared to DMSO treated mice
(Figure 8b,c). No differences were seen in small and medium tumor size between the two
groups.
DCQ induces colon tumor specific apoptosis while preserving normal colon epithelium
We showed in the Balb/c mouse xenograft model that DCQ given at a 17 mg/kg
dosage effectively increased tumor tissue apoptosis and decreased proliferation while not
indicating toxicity to liver, kidney and brain tissue. (Figure 2, 3, and 6). To further
elucidate the effectiveness and safety of DCQ, apoptosis and proliferation data was
obtained in identified tumors of Apcmin/+ mice within the colon (Figure 9). Tissue sections
were specifically cut to obtain a large amount of colon tissue in an effort to obtain the
surrounding normal colon epithelium for analysis which would be also used to observe
colon histopathology and any apoptotic activity occurring within the normal colon
epithelium (Figure 10). Within the tumor, DCQ treated mice had significantly greater
apoptotic activity (p < 0.001) and significantly lower proliferative activity (p < 0.05),
these findings paralleling the finding in the Balb/c xenograft model. Observing the
obtained TUNEL stain of the surrounding normal colon tissue, no increased apoptotic
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activity was observed, indicating DCQ only induced apoptosis to the tumor tissue (Figure
10). The WT TUNEL stain was performed as a negative control.
DCQ targets HIF-1α pathway and induces intracellular death in colon tumors of Apcmin/+
mice
Functional cross-talk has been reported between HIF-1α and the Apc gene at the
transcriptional level. Newton et. al., 2010 reported a consistent direct transcriptional
repression of Apc by HIF-1α in multiple cell lines. HIF-1α when bound to a hypoxiaresponsive element, dubbed HRE, in the APC promoter region in the presence of
hypoxia. Therefore, the Apcmin/+ model of colorectal cancer provided an interesting target
for testing the effectiveness of DCQ on reducing the hypoxic signaling within the tumor
tissue. Colon tumors excised from the DCQ treated Apcmin/+ mice showed nearly nondetectable nuclear HIF-1α protein expression (p < 0.05) when compared to DMSO
treated mice (Figure 11a, b).
Along with these findings, we also saw an increased pro-apoptotic protein Bax (p
< 0.05) and decreased anti-apoptotic protein Bcl-2 (p < 0.05) in DCQ treated mice
compared to DMSO treated controls (Figure 12 a, b, c). Thus, effectively decreasing the
Bcl-2 to Bax ratio within the tumor. These results were parallel to the data obtained from
the Balb/c xenograft tumors.
DCQ treated mice Apcmin/+mice experience less liver apoptosis and no indications of
kidney or brain apoptosis
As was done with the Balb/c treated mice, we investigated the safety of the 17
mg/kg DCQ dosage by TUNEL staining excised liver, kidney, and brain tissue from the
treated Apcmin/+ mice. Similar to the Balb/c mice, no apoptosis was detected in the kidney
or brain tissue of DMSO or DCQ treated mice (Figure 14 a). However, DCQ treated mice
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showed a significantly lower (p < 0.01) amount of apoptotic cells compared to DMSO
treated control mice (Figure 14 a,b). These results show less cell death was occurring in
the livers of DCQ treated mice.
3.5 Discussion
Despite advancements in cancer prevention and treatment methods the burden of
colorectal cancer costs the United States over 51,000 lives and $12.2 billion dollars in
2012 alone, $10.7 billion being due to lost productivity and premature death. Two of the
most significant and most investigated hallmarks of cancer are the tumor’s ability to
sustain an abnormally high level of proliferative signaling and to resist apoptotic
signaling. A major contributor to these hallmarks is the chronic hypoxia present in the
tumor environment which activates the HIF-1α pathway. This hypoxic response is
especially true in the already hypoxic environment of the mammalian colon.
Identification of this trait has led to drug engineering that is aimed at targeting the
hypoxic environment as a method of directly utilizing the hypoxic regions of against the
tumor. The current study was aimed at investigating the safety and effectiveness of the
novel hypoxia targeting drug 2-benzoyl-3-phenyl 6,7-dichloroquinoxaline 1,4-dioxide
(DCQ). We report the novel finding that the maximal tolerated dose of 17 mg/kg is both
effective in inducing colorectal tumor cell apoptosis and blocking tumor cell proliferation
in two models of colorectal cancer and is safe at current dosage by showing a lack of
normal tissue death. This study also indicated DCQ is capable of reducing critical
hypoxia signaling protein HIF-1α and leads to up-regulation of pro-apoptotic and
reduction of anti-apoptotic genes involved in intracellular apoptosis signaling within the
tumor.
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Previous investigations completed at the American University of Beirut have
shown that DCQ is a hypoxia activated compound that is effective at inducing tumor
specific apoptosis and also has increased effectiveness when supplemented with acute
doses of radiation in-vitro (Diab‐Assef et al., 2002; El-Khatib et al., 2010; Gali-Muhtasib,
Diab-Assaf, et al., 2004; Haykal et al., 2008, 2009; Itani et al., 2007). The most recent
investigation completed at the American University of Beirut identified a maximal
tolerated dosage in mice of 17 mg/kg in healthy mice (Ghattass et al., 2014). The next
step in further progressing the understanding of DCQ was to design an investigation that
would translate the compound’s ability to effectively reduce tumor burden in animals at a
progressed stage of colorectal cancer. This study, therefore, was designed to evaluate two
animal models of colorectal cancer which investigated the clinical safety and
effectiveness in both a tumor xenograft model and a genetic model of colorectal cancer.
Balb/c implanted with CT-26 tumor xenografts given 4 weeks of a semiweekly
17mg/kg DCQ treatment showed reduced tumor size and weight. Tumor tissue was
stained for presence of apoptosis and proliferation, and the data indicate that tumors of
DCQ treated mice had significantly greater apoptosis and lower proliferation compared to
control mice. Similar results are reported for the 20 week old Apcmin/+ mice treated with
the same 4 week semiweekly treatment plan as Balb/c mice. The two animal models,
Balb/c implant mice and Apcmin/+ mice were not compared. DCQ treated Apcmin+ mice
showed significantly lower clinical score after just one week of treatment and continued a
downward trend in clinical score until time of sacrifice. The average life of an Apcmin/+
mouse is approximately 120 days or 18 weeks of age. DMSO treated control mice to
survive just past 19 weeks of age but the life of all DCQ treated mice was extended to 21

56

weeks of age. The major factor of the reduction in clinical score was through the reduced
diarrhea and fecal hemoccult scores, both significant clinical indications of advanced
intestinal and colorectal cancer. Collectively, these results demonstrate that the 17 mg/kg
dosage is effective in reducing tumor burden in both an implanted tumor model and a
genetic model of intestinal and colorectal cancer. We would like to note that although
tumor counting from the intestines of the Apcmin/+ mice showed a decreased total tumor
count and large tumor size in DCQ treated mice, total number of tumors reported was
noticeably lower than most previously reported studies involving Apcmin/+ mouse models
(Balmain, Gray, & Ponder, 2003; Johnson & Fleet, 2013; Moser et al., 1990).
The data from this study provide evidence that DCQ treatment in Apcmin/+ mice
induced tumor apoptosis and did not induce normal colon tissue death. Clinically, this
finding is exciting because many drugs failing to accomplish this feat. This supports the
previous findings by the group at the American University of Beirut that DCQ works in a
tumor specific manner to induce only tumor cell apoptosis while preserving normal colon
tissue. Protein analysis in tumors from both animal models indicate the down-regulation
of nuclear transcription protein HIF-1α with DCQ treatment. The key moiety of the DCQ
compound is at the 1,4-dioxide structure. In a hypoxic environment, electron transfer is
more likely to occur to the 1,4-dioxide moiety due to the highly reducing conditions of
the hypoxic cells, this allows a compound such as DCQ to utilize the hypoxic areas of
tumors as a targeting element to the cytotoxicity of these compounds. A study by
(Newton et. al, 2010) provided evidence of functional cross-talk between HIF-1α and the
Apc gene at the transcriptional level. This relationship was confirmed in an Apc depletion
model which showed an increased HIF-1α expression and activity in tumor cells. In the

57

present study, the nearly non-detectable HIF-1α protein expression in DCQ treated
Apcmin/+ mice are an exciting find, this data indicating that DCQ has the ability to reduce
critical nuclear transcription factor HIF-1α in the tumor environment in-vivo. However,
we cannot suggest any specific mechanistic results without further mechanistic studies
that would confirm the effectiveness of DCQ in reversing the increased hypoxia in
tumors with Apc gene deletion.
Previously established is that the HIF-1α pathway, when highly expressed in a
tumor environment, increases transcription of trophic factors such as VEGF, which can
lead to the inhibition of intracellular apoptosis through phosphorylation of the PI-3kinase.
Once activated, the PI-3kinase will ultimately lead to the phosphorylation of proapoptotic protein Bad which increases the Bcl-2:Bax ratio and prevents cell apoptosis. An
investigation by Gali-Muhtasib, Diab-Assaf, et al., 2004 at the American University of
Beirut reported DCQ increased pro-apoptotic protein Bax and decreased anti-apoptotic
protein Bcl-2 in multiple human cell lines. We have evidence that in-vivo this response is
activated in the tumor cells of both a xenograft and genetic model of intestinal/ colorectal
cancer after 4 weeks of semiweekly DCQ treatment at 17 mg/kg. This study serves as the
translational step to the animal use of the drug and indicates DCQ induces tumor cell
apoptosis by increasing intracellular expression of pro-apoptotic proteins and decreasing
anti-apoptotic proteins and warrants further animal and mechanistic investigations to
observe the complete anti-tumor mechanisms of DCQ.
Another interesting find was the decreased incidence of liver apoptosis in Apcmin/+
mice treated with DCQ. Liver toxicity and hypertrophy is a trademark trait of colorectal
cancer progression and cancer cachexia (Narsale et al., 2015). The decreased liver
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apoptosis suggests a decreased tumor burden as a result of DCQ treatment, however, the
data does not indicate a direct relationship between DCQ and decreased liver apoptosis
and warrants further investigations to observe if DCQ has a direct effect on preserving
liver function.
Conclusion
The involvement of hypoxia in the progression of colorectal cancer has led to the
development of hypoxia targeting chemotherapeutics, however, none of which have
shown to be safe and effective in eradicating colorectal tumors. In the present study,
novel compound DCQ is shown as safe and effective in reducing tumor burden in
xenograft and genetic models of colorectal cancer. DCQ, given semiweekly at 17 mg/kg
for 4 weeks was effective at inducing tumor specific apoptosis and reducing tumor tissue
proliferation while preserving normal colon tissue and without inducing apoptosis to vital
organs. We also showed the down-regulation of critical hypoxia gene HIF-1α and the upregulation of pro-apoptotic gene paralleled by decreased anti-apoptotic genes involved in
regulation of the intracellular apoptosis pathway within the tumors of both Balb/c and
Apcmin/+ mice treated with DCQ. Additional experiments are needed to be performed to
establish the complete understanding of the anti-tumor mechanisms of DCQ, and should
be pursued as a future line of review for understanding the use of DCQ as a legitimate
chemotherapeutic compound.
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Table 3.1 Apcmin/+ mouse clinical score guidelines. Clinical score was monitored on all
ten Apcmin/+ mice from 8 weeks of age until sacrifice. Body weight loss was determined
as percent (%) loss from 8 weeks of age. Fecal Hemoccult and diarrhea was evaluated
during every clinical visit.

Body Weight Loss

Fecal Hemoccult

Diarrhea

5% = 0
6-10% = 1
11-15% = 2
16-20% = 3
>20% = 4

No blood = 0
Some blood = 2
Severe bleeding = 4

Hard Stool = 0
Soft Stool = 2
Runny and soft = 4
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3.6 Figure Legend
Figure 3.1 Experimental Design. (A) At 10 weeks of age, sixteen Balb/c mice were
randomly assigned to a DMSO (control) or DCQ treatment group and implanted with 2 x
106 CT-26 cells. Tumors were allowed to grow for 2 weeks before receiving bi-weekly
injections of either DMSO or DCQ over a 4 week period. (B) At 8 weeks of age, ten
Apcmin/+mice were randomly assigned to a DMSO (control) or DCQ treatment group and
began clinical evaluation. At 16 weeks of age, mice began receiving a bi-weekly injection
of either DMSO or DCQ over a 4 week period. Clinical evaluations were taken bi-weekly
through the course of the experiment. # = CT-26 tumor implantation, ** = Begin Apcmin/+
clinical evaluation, * = DMSO or 17mg/kg DCQ injection.
Figure 3.2 DCQ therapy decreases tumor xenograft weight and area. Balb/c with
flank tumor and final tumor weight and area. (A) Images of Balb/c mice with flank tumor
at beginning of therapy (Day 1) and after 4 weeks (Day 28) of DMSO or DCQ injection.
(B) Subcutaneous tumors removed and weighed at time of sacrifice in grams (g). (C)
Final tumor area measured prior to sacrifice in millimeters squared (mm^2). Values are
means ± standard error. *p<0.05.
Figure 3.3 DCQ increases apoptosis in tumor xenografts of Balb/c mice. Tumor
Apoptosis: (A) TUNEL assay of tumor tissues imaged at 4x and 20x of DMSO and DCQ
injected mice. (B) Percent total apoptotic area of tumor tissue. Arrows indicate examples
of positively labeled cells. Values are means ± standard error. *p<0.05.
Figure 3.4 DCQ decreases proliferation in tumor xenografts of Balb/c mice. Tumor
Proliferation: (A) BrdU assay of tumor tissues imaged at 4x and 20x of DMSO and DCQ
injected mice. (B) Percent total proliferative area of BrdU positive cells. Arrows indicate
examples of positively labeled cells. Values are means ± standard error. *p<0.05.
Figure 3.5 DCQ decreases nuclear HIF-1α protein expression in tumor xenografts of
Balb/c mice. (A) Nuclear expression of HIF-1α protein is decreased in mice given DCQ
treatment compared to DMSO control. Quantification of HIF-1α (B) and HIF-1 (C) levels
is shown as integrated optical density as determined by densiometry analysis. Values are
means ± standard error. *p< 0.05.
Figure 3.6 DCQ increases pro-apoptotic proteins Cleaved Caspase-9,
Dephosphorylated-Bad, and Bax and decreases anti-apoptotic protein Bcl-2 in
tumor xenografts of Balb/c Mice. (A) Cytoplasmic expression of Cleaved Caspase-9,
Dephosphorylated-Bad (Dephos-Bad), and Bax pro-apoptotic proteins and anti-apoptotic
protein Bcl-2 in DMSO and DCQ treated Balb/c mice. (B-E) Quantification of CleavedCaspase-9, Dephos-Bad, Bax, and Bcl-2 is shown as integrated optical density as
determined by densiometry analysis, respectively. Values are means ± standard error. * p
< 0.05, # p < 0.001.
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Figure 3.7 DCQ treatment may not induce liver, kidney, or brain apoptosis in Balb/c
mice. Photographs of liver, kidney, and brain of Balb/c mice with CT-26 xenografts
given DMSO or DCQ. Absence of brown labeled cells indicates no increased apoptosis in
DCQ treated mice.
Figure 3.8 DCQ improves Apcmin/+ mouse clinical score after 4 weeks of treatment.
(A) Clinical scores for DMSO and DCQ treated Apcmim/+ mice during the 13 weeks of
study. Weight loss, diarrhea and blood in stools were used as parameters to calculate the
clinical score (Table 1). Statistical significance was only tested from 16 weeks of age to
sacrifice between both treatment groups. (B) Photographs of mouse showing regressed
rectal prolapse after 1 week of DCQ treatment. Values are means ± standard error. * p <
0.05.
Figure 3.9 DCQ reduces Apcmin/+ mouse intestinal tumor count and size. (A)
Representative photographs of methylene blue-stained intestinal tissues for DMSO and
DCQ treated Apcmin/+ mice. Difference in total poly number (B) and polyp size (C) were
measured in Apcmin/+ treated with DMSO and DCQ. Values are means ± standard error. *
p <0 .05.
Figure 3.10 DCQ induces colon tumor apoptosis and decreases tumor proliferation
of Apcmin/+ mice. TUNEL and BrdU assays were performed to observe and measure
apoptotic activity and proliferative cells in identified colonic tumors of Apcmin/+ mice
given DMSO and DCQ treatements. Average positively labeled apoptotic cells (A) and
proliferating (B) cells in identified colonic tumors of DMSO and DCQ treated mice. (C)
Representative photographs of TUNEL and BrdU assayed colonic tumors. Arrows
indicate examples of positively labeled cells. Values are means ± standard error. * p <
0.05, # p < 0.001.
Figure 3.11 DCQ does not induce normal colon epithelium apoptosis in Apcmin/+
mice. Identified normal colon tissue of WT, DMSO and DCQ treated mice was stained
with hematoxylin and eosin and also observed for apoptosis via TUNEL assay. TUNEL
assay WT representative was treated as a negative control.
Figure 3.12 DCQ decreases nuclear expression of HIF-1α in colon tumors of Apcmin/+
mice. (A) Nuclear expression of HIF-1α protein is decreased in mice given DCQ
treatment compared to DMSO control. (B) Quantification of HIF-1α levels is shown as
integrated optical density as determined by densiometry analysis. Values are means ±
standard error. * p < 0.05.
Figure 3.13 DCQ increases pro-apoptotic proteins Cleaved Caspase-9 and Bax and
decreases anti-apoptotic protein Bcl-2 in colon tumors Apcmin/+ mice. (A)
Cytoplasmic expression of Bax pro-apoptotic protein and anti-apoptotic protein Bcl-2 in
DMSO and DCQ treated Balb/c mice. Quantification of Bax (B) and Bcl-2 (C) is shown
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as integrated optical density as determined by densiometry analysis, respectively. Values
are means ± standard error. * p < 0.05.
Figure 3.14 DCQ treatment decreases liver apoptosis and does not induce kidney or
brain tissue apoptosis in Apcmin/+ mice. (A) Photographs of liver, kidney, and brain of
Apcmin/+ mice treated with DMSO or DCQ. A decreased amount of apoptotic cells in the
liver was noticed indicating less apoptosis and liver toxicity in DCQ treated mice. Arrows
indicate examples of positively labeled cells. (B) Average positively labeled apoptotic
cells of liver tissue measured. Values are means ± standard error. * p < 0.001.
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Figure 3.1 Experimental Design.
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Figure 3.2 DCQ therapy decreases tumor xenograft weight and area.
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Figure 3.3 DCQ increases apoptosis in tumor xenografts of Balb/c mice.
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Figure 3.4 DCQ decreases proliferation in tumor xenografts of Balb/c mice.
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Figure 3.6 DCQ increases pro-apoptotic proteins Cleaved Caspase-9,
Dephosphorylated-Bad, and Bax and decreases anti-apoptotic protein Bcl-2 in
tumor xenografts of Balb/c Mice.
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Figure 3.7 DCQ treatment may not induce liver, kidney, or brain apoptosis in Balb/c
mice.
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Figure 3.8 DCQ improves Apcmin/+ mouse clinical score after 4 weeks of treatment.
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Figure 3.9 DCQ reduces Apcmin/+ mouse intestinal tumor count and size.
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Figure 3.10 DCQ induces colon tumor apoptosis and decreases tumor proliferation
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Figure 3.11 DCQ induces tumor specific apoptosis and decreases tumor
proliferation in colon tumors of Apcmin/+ mice.
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Figure 3.13 DCQ increases pro-apoptotic protein Bax and decreases anti-apoptotic
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DETAILED AIMS AND METHODOLOGY
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Specific Aim #1 will evaluate the safety and effectiveness of the 17mg/kg DCQ
dosage in a xenograft and genetic model of colorectal cancer.
Rationale: It has been previously shown that DCQ is effective in causing tumor
specific apoptosis and can repress tumor growth in multiple human cancer cell lines
through activation mechanisms involving down-regulation of HIF-1α pathway (DiabAssef et al., 2002; El-Khatib et al., 2010; H. U. Gali-Muhtasib et al., 2005; Ghattass et
al., 2014; Haykal et al., 2008, 2009). Toxicity studies from the American University of
Beirut have suggested a concentration of 17mg/kg dose will be effective in causing tumor
cell apoptosis while staying below systemic toxic levels, therefore preserving essential
healthy tissue in both the GI system and the entire body. The 17mg/kg dosage has
previously been shown to be effective in a breast cancer xenograft study however DCQ
has yet to be investigated in-vivo for clinical effectiveness in a colorectal cancer model
(Ghattass et al., 2014). Thus, we would like to investigate the safety and clinical
effectiveness of the 17mg/kg dose in a tumor implant and genetic model of colorectal
cancer.
Experimental design for specific aim #1. Experiment 1 will determine the safety and
clinical effectiveness of DCQ in 10 week old Balb/c mice implanted with CT-26 murine
colorectal tumor cells and in 16 week old Apcmin/+ mice.
At approximately 10 weeks of age, Balb/c mice will be randomized to a control
group or treatment group. 2 million CT-26 cells, kindly provided by Dr. Marj Pena, were
injected subcutaneously into the right flank of each mouse and allowed to grow for 2
weeks. After 2 weeks DCQ will be dissolved in DMSO to create a 17mg/kg
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concentration in a 100μL dose and injected twice a week for four weeks. Control mice
will receive a 100μL injection of sterile DMSO twice a week for four weeks. At 10 weeks
of age, Balb/c mice will be approximately 20g and will be able to withstand the tumor
burden and chemotherapy treatments. Apcmin/+ mice were aged to 8 weeks of age and
randomized into control and treatment groups. Twice a week, clinical evaluations will be
conducted to measure body weight, food and water consumption, fecal hemoccult and
diarrhea, and a description of any abnormal behavior or side effects that might be arising
as part of the therapy. At 16 weeks of age, mice in their respective groups will receive a
bi weekly 100μL injection of either DMSO or 17mg/kg of DCQ. Min mice have initiated
body weight loss and intestinal polyp development and show a near maximum clinical
score by 15-16 weeks of age, making it an ideal time point to assess the effectiveness of
DCQ on the treatment of colorectal cancer. All mice will be housed in standard cages for
the duration of the study. Body weight and tumor dimensions in Balb/c mice and clinical
score in Apcmin/+ mice will be measured at the time of each treatment period and at the
time of sacrifice. At sacrifice, brain, liver, kidney, spleen, and plasma will be collected
from all mice, tumor xenografts will also be taken from Balb/c mice, and colon and small
intestine will also be collected from Apcmin/+ mice. Sections of tumor xenografts, brain,
liver, kidney, colon, and small intestine from respective mice will be fixed in 10%
formalin for 24 hours, preserved in 70% ethanol, and then embedded in paraffin wax to
be sectioned for immunohistochemistry. All tissues extracted will also be weighted and
frozen for protein analysis.
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Experiment #1 will determine the safety and effectiveness of DCQ in a tumor xenograft
and genetic animal model of colorectal cancer.
Animals: Balb/c male mice will be bred with female Balb/c mine in the USC Discovery
building Arnold School of Public Health animal resource facility. All mice will be
provided with standard rodent chow (Harlan Teklad Rodent Diet, #8604, Madison, WI)
and water ad libitum. Body weights will be measured throughout the course of the study.
At 10 weeks of age, mice will be injected by a member of Dr. Marj Pena's lab with 2
million cultured CT-26 murine colorectal cancer cells each and assigned into one of two
groups; control or DCQ treatment. Apcmin/+ male mice on a C57BL/6 background will be
bred with female C57BL/6 mice in the Discovery building Arnold School of Public
Health animal resource facility. Animals will be genotyped as heterozygous for the Apc
gene. All mice will be provided with standard rodent chow (Harlan Teklad Rodent Diet,
#8604, Madison, WI) and water ad libitum. All mice will undergo clinical evaluation and
receive clinical scores based on the protocol and guidelines of the Fayad lab. At 8 weeks
of age, mice will be assigned to one of two groups; control or DCQ treatment. DCQ was
synthesized from 5,6-dichlorobenzofurazan oxide and dibenzoylmethane via the Beirut
reaction by Dr. Makhluf J. Haddadin and provided by Dr. Hala Gali-Muhtasib (American
University of Beirut, Beirut, Lebanon). After two weeks of tumor growth, Balb/c mice
will begin a bi-weekly treatment period. DCQ treatment will consist of a bi-weekly
100μL intraperitoneal injection of DCQ dissolved in DMSO at a concentration of
17mg/kg body weight. Balb/c control mice will receive a bi-weekly vehicle injection of
100μL of DMSO. Balb/c mice will be sacrificed at 16 weeks of age after 4 weeks of
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treatment. At 16 weeks of age, Apcmin/+ mice will receive either a bi-weekly
intraperitoneal 100μL injection of DMSO or DCQ at a concentration of 17mg/kg body
weight. All mice will be sacrificed at 20 weeks of age after a 4 week treatment period.
Based on previous drug development preliminary studies and on animal data from our
lab, 5-6 mice per group are sufficient to detect a difference in clinical and experimental
data.
Table A.1 Animal treatment groups for experiment #1.

Strain

Treatment

Age
(weeks)

Balb/c

DMSO

10-16

5-6

Balb/c

DCQ

10-16

5-6

Apcmin/+

DMSO

8-20

5-6

Apcmin/+

DCQ

8-20

5-6

N

Table A.2 Animal clinical score guidelines
Body Weight Loss Fecal Hemoccult

Diarrhea

5% = 0

No blood = 0

Hard Stool = 0

6-10% = 1

Some blood = 1

Soft stool = 1

11-15% = 2

Sever bleeding = 2

Runny and soft = 2

16-20% = 3
>20% = 4
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Primary Outcomes
Tumor size and weight:
Tumor size will be evaluated at each treatment period in Balb/c mice. At sacrifice, tumor
will be removed from the mice and weighed.
Clinical Score:
Clinical score in Apcmin/+ mice will be evaluated from 8 weeks of age through time of
sacrifice.
Systemic toxicity: Brain, liver, and kidney will be analyzed for presence of apoptosis via
TUNEL assay. Serum levels of IL-6 will be assessed via ELISA also to determine
relative levels of systemic inflammation.
Secondary outcomes:
Body composition: DEXA scan will be performed on each mouse prior to sacrifice and
be used to determine between group differences in body composition after 4 weeks of
therapy.
Specific Methodology Aim #1:
Animals: Balb/c male mice will be bred with female Balb/c mice in the Discovery
building Arnold School of Public Health animal resource facility. Apcmin/+ male mice on a
C57BL/6 background will be bred with female C57BL/6 mice in the Discovery building
Arnold School of Public Health animal resource facility. Resulting heterozygous mice
from the Apcmin/+ cross will develop intestinal and colonic tumors as early as 8 weeks of
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age and typically have a life span of 20-22 weeks of age. All animals will be housed in
standard cages and the room will be maintained on a 12:12 light:dark cycle with the light
period starting at 0700. Mice will be provided with standard rodent chow (Harlan Teklad
Rodent Diet #8604) and water ad libitum. Body weight and tumor size will be monitored
during the course of the study, final tumor weight will be measured at time of sacrifice.
All animals at time of sacrifice will be injected with 1mg of BRDU dissolved in
phosphate buffered saline (PBS) and undergo DEXA scan prior to blood draw and
cervical dislocation. All animal experimentation is approved by the University of South
Carolina's Institutional Animal Care and Use Committee. Tumor growth will be allowed
to occur for 2 weeks until treatment periods will begin. At this point, DCQ will be
prepared in DMSO so as to obtain a concentration of 17mg/kg in a 100μl injection
normalized to the average weight of the mice.
Genotyping: All animals from the Apcmin/+ cross will be genotyped using a tail snip. At 45 weeks of age; animals will be weaned, numbered, and a small tail snip (~1-2mm)
collected. The tail snip is digested in 200μL of tail digest buffer and 5μL of proteinase K.
Tails are incubated overnight in a water bath set at 55OC. After incubation, samples are
heat shocked at 95OC in a dri-bath for 10 minutes. Heterozygosity of the Apc gene will be
determined via a PCR reaction (Apc forward 5' TGAGAAAGACAGAAGTTA 3', reverse
5' TTCCACTTTGGCATAAGGC 3'). PCR products are run out on a 5% polyacrylamide
gel and exposed to UV light. Presence of a band indicates heterozygosity of the Apc gene.
Tissue Collection: Mice will be anesthetized via exposure to an isofluorane and oxygen
mixture. Blood will be collected from the retro-orbital sinus using a capillary tube. Blood
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will be spun at 4OC, 10,000rpm, for 10 minutes. Plasma will then be pipetted off and
stored at -80OC until analysis. Brain (br), liver (l), kidney (k), spleen (sp), and tumor
xenografts (tmr) from Balb/c mice will be excised, rinsed in PBS, frozen in a dry ice box,
and stored at -80OC until further analysis. Parts of each tissue will also be fixed in 10%
formalin for 24 hours, preserved in 70% ethanol, and then embedded in paraffin wax for
histological sectioning. Small intestine, and colon from the Apcmin/+ mice will be chosen
for sections containing tumors will be fixed in 10% formalin for 24hours, preserved in
70% ethanol, and then embedded in paraffin wax for histological sectioning, brain (br),
liver (l), kidney (k), spleen (sp) will also be collected. Parts of each tissue will also be
excised, rinsed in PBS, frozen in a dry ice box, and stored at -800C until further analysis.
Remaining sections of the small intestine will be rinsed with PBS and opened
longitudinally. Sections will be fixed in 10% formalin for 24 hours and then preserved in
70% ethanol and used for intestinal tumor counts in the Apcmin/+ mice.
Polyp count: Intestinal polyps will be counted by staining in methylene blue. Formalin
fixed intestinal sections from all Apcmin/+ mice were rinsed in deionized water, briefly
stained in 0.1 % methylene blue, and counted by the same investigator who was blinded
to the treatments. Polyps were counted under a dissecting microscope, using forceps to
pick through the intestinal villi and identify polyps. Polyps were categorized as ≥ 1 mm
or < 1mm in the small intestine and > 2 mm, 1-2 mm, and < 1 mm in the large intestine.
After polyps were counted, intestinal sections were placed in 70 % ethanol for further
analysis. Pilot data yielded an interassay coefficient of variation of 4 %.
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Plasma IL-6: Plasma IL-6 will be measured using a mouse specific ELISA kit.
Approximately 25-50μL of plasma will be incubated. A standard curve will be used to
determine the levels of circulating IL-6 in all samples after treatment with DCQ or
DMSO. An ELISA plate will be coated with capture antibody using a coating buffer and
set to incubate in 4OC overnight. After washing the plate 100μL of blocking solution is
added for 1 hour. After three washes, 100μL of standard or diluted sample is added to the
wells in duplicate and incubated for 1hr. After 7 washes, 100μL of TMB cocktail is added
to each well and stored in the dark for 30 minutes. 50μL of Stop solution is added to the
wells and the plate is read at 450nm and 570nm according to the manufacturer's
instructions.
Hematoxylin and Eosin Staining (H&E): Transverse sections (~5μm) will be cut from the
paraffin embedded kidney and liver of Balb/c and Apcmin/+ mice on a rotary microtome.
Cut tissues will be allowed to expand on a 400C -450C water bath and then attached to (+)
charged saline coated microscope slides. Excess paraffin is removed by placing slides in
a 650C oven for 1hr and then stored at 40C until staining. Sections will be warmed to
room temperature for 5-10minutes. Tissue morphology will be analyzed by observation
and comparison to healthy tissue control sections. Sections are deparaffinized using the
following washing progression; 3x5min xylene washes, 2x5min 100% EtOH, 1x3min
95% EtOH, and 1x3min 70% EtOH. Sections are then washed for 5min in dH2O, stained
with filtered hematoxylin for 5min, then again washed 6x5 in dH2O. Sections are washed
in acid alcohol mix (160mL 100% EtOH, 1mL acetic acid, and volumed to 200mL with
dH2O) for 6 dips then again washed in dH2O for 4 dips. Sections are then washed in
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Ammonia H2O (0.6mL Ammonium OH volumed to 200mL with dH2O) for 6 dips and
then again washed in dH2O for 10min. The sections will then be stained with Eosin for
3min and dehydrated in the following alcohol progression; 1x2min 70% EtOH, 1x2min
95% EtOH, 2x3min 100% EtOH, and 2x5min xylene. Sections are allowed to air dry for
30min and then mounted for viewing with Permount mounting media. Digital
photographs will be taken from each section at a 4x, 20x and 40x with a Nikon E600
Widefield Epifluorescence and Darkfield Microscopy System at the University of South
Carolina School of Medicine, and morphology examined.

TUNEL Assay: Transverse sections (~5μm) will be cut from the paraffin embedded
brain, kidney, and liver of Balb/c and Apcmin/+ mice on a rotary microtome. Cut tissues
will be allowed to expand on a 400C -450C water bath and then attached to (+) charged
saline coated microscope slides. Excess paraffin is removed by placing slides in a 650C
oven for 1hr and then stored at 40C until staining. Refrigerated sections will be warmed to
room temperature for 5-10minutes. Sections will be stained for apoptotic tissue using
Apop-Tag kit from Millipore (S7100). Sections are deparaffinized using the following
washing progression; 3x5min xylene washes, 2x5min 100% EtOH, 1x3min 95% EtOH,
and 1x3min 70% EtOH. Sections are then washed for 5min in 1X PBS and covered in
20μg/ml proteinase K diluted from stock in fresh 1X PBS for 15min to remove any
possible contaminants and inactivate nucleases that would degrade apoptotic tissue. After
a 2x2min wash in dH2O the sections are blocked in 3% H2O2 for 5min at room
temperature. After blocking the sections are washed 2x5min in PBS and incubated for
2.5hrs in a humidified chamber in a working solution of TdT enzyme at 370C. Enzymatic
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reaction is stopped using a working strength stop solution for 10min and then washed for
3min in PBS. Anti-dioxigenin conjugate is then applied to each section and incubated for
30min at room temperature in a humidified chamber. After incubation sections are
washed 4x2min in PBS and detection reagent DAB is applied to develop the desired
intensity of potentially positive cells. After washing in 3x1min and 1x5min dH2O, slides
are counterstained for 30sec with 5% methyl green and washed in dH2O until
counterstain no longer fades. Slides are then mounted for viewing with Permount
mounting media after a minimum 3hr drying period. Digital photographs will be taken
from each section at a 4x, 20x and 40x with a Nikon E600 Widefield Epifluorescence and
Darkfield Microscopy System at the University of South Carolina School of Medicine,
and percent apoptotic tissue will be determined with imaging software (ImageJ,
Bethesda, MD).

Specific Aim #2: will determine the mechanism of action of DCQ in the two animal
models of colorectal cancer.
Rationale: Studies in multiple human cell lines from the American University of
Beirut have shown consistent results of increased mitochondrial induced apoptosis with
DCQ treatment. The CT-26 xenograft and Apcmin/+ transgenic mouse are common
experimental models of colorectal cancer. The mutated Apc gene causes activation of the
Wnt/β-catenin pathway which is responsible for tumorgenesis in the colon and small
intestines (Bienz & Clevers, 2000; Leclerc et al., 2004; Newton et al., 2010; Näthke &
Rocha, 2011). Although this is a specific genetic model of cancer there is genetic
variability in the tumor formation and therefore each tumor site is expected to respond
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differently to drug treatment. HIF-1α and the Apc gene have been shown to have crosscommunication at the transcriptional level which serves as a driving force for intestinal
tumorgenesis (Mehl et al., 2005; Newton et al., 2010; Yamulla et al., 2014). Since it has
been determined that DCQ works through interruption of the HIF-1α pathway, we are
interested in mechanistic differences between and within the murine CT-26 tumor
xenograft model and Apcmin/+ genetic model of colorectal cancer.

Experimental design for specific aim #2. Experiment 2 will evaluate the mechanism of
action of DCQ inducing tumor specific apoptosis in a xenograft and genetic model of
colorectal cancer.

The same mice from Aim #1 will be used for Aim #2. At approximately 10 weeks of age,
Balb/c mice will be randomized to a control group or treatment group. 2 million CT-26
cells, kindly provided by Dr. Marj Pena, were injected subcutaneously into the right flank
of each mouse and allowed to grow for 2 weeks. After 2 weeks DCQ will be dissolved in
DMSO to create a 17mg/kg concentration in a 100μL dose and injected twice a week for
four weeks. Control mice will receive a 100μL injection of sterile DMSO twice a week
for four weeks. At 10 weeks of age, Balb/c mice will be approximately 20g and will be
able to withstand the tumor burden and chemotherapy treatments. Apcmin/+ mice were
aged to 8 weeks of age and randomized into control and treatment groups. Twice a week,
clinical evaluations will be conducted to measure body weight, food and water
consumption, fecal hemoccult and diarrhea, and a description of any abnormal behavior
or side effects that might be arising as part of the therapy. At 16 weeks of age, mice in
their respective groups will receive a bi weekly 100μL injection of either DMSO or
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17mg/kg of DCQ. Min mice have initiated body weight loss and intestinal polyp
development and show a near maximum clinical score by 15-16 weeks of age, making it
an ideal time point to assess the effectiveness of DCQ on the treatment of colorectal
cancer. All mice will be housed in standard cages for the duration of the study. Body
weight and tumor dimensions in Balb/c mice and clinical score in Apcmin/+ mice will be
measured at the time of each treatment period and at the time of sacrifice. At sacrifice,
brain, liver, kidney, spleen, and plasma will be collected from all mice, tumor xenografts
will also be taken from Balb/c mice, and colon and small intestine will also be collected
from Apcmin/+ mice. Sections of tumor xenografts, brain, liver, kidney, colon, and small
intestine from respective mice will be fixed in 10% formalin for 24 hours, preserved in
70% ethanol, and then embedded in paraffin wax to be sectioned for
immunohistochemistry. All tissues extracted will also be weighted and frozen for tissue
analysis of hypoxia markers and intracellular apoptosis markers.

Experiment #2 will determine the mechanism of action of DCQ in two animal models of
colorectal cancer.
Animals: The same mice from Aim #1 will be used in Aim #2. Balb/c male mice will be
bred with female Balb/c mine in the USC Discovery building Arnold School of Public
Health animal resource facility. All mice will be provided with standard rodent chow
(Harlan Teklad Rodent Diet, #8604, Madison, WI) and water ad libitum. Body weights
will be measured throughout the course of the study. At 10 weeks of age, mice will be
injected by a member of Dr. Marj Pena's lab with 2 million cultured CT-26 murine
colorectal cancer cells each and assigned into one of two groups; control or DCQ
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treatment. Apcmin/+ male mice on a C57BL/6 background will be bred with female
C57BL/6 mice in the Discovery building Arnold School of Public Health animal resource
facility. Animals will be genotyped as heterozygous for the Apc gene. All mice will be
provided with standard rodent chow (Harlan Teklad Rodent Diet, #8604, Madison, WI)
and water ad libitum. All mice will undergo clinical evaluation and receive clinical scores
based on the protocol and guidelines of the Fayad lab. At 8 weeks of age, mice will be
assigned to one of two groups; control or DCQ treatment. DCQ was synthesized from
5,6-dichlorobenzofurazan oxide and dibenzoylmethane via the Beirut reaction by Dr.
Makhluf J. Haddadin and provided by Dr. Hala Gali-Muhtasib (American University of
Beirut, Beirut, Lebanon). After two weeks of tumor growth, Balb/c mice will begin a biweekly treatment period. DCQ treatment will consist of a bi-weekly 100μL
intraperitoneal injection of DCQ dissolved in DMSO at a concentration of 17mg/kg body
weight. Balb/c control mice will receive a bi-weekly vehicle injection of 100μL of
DMSO. Balb/c mice will be sacrificed at 16 weeks of age after 4 weeks of treatment. At
16 weeks of age, Apcmin/+ mice will receive either a bi-weekly intraperitoneal 100μL
injection of DMSO or DCQ at a concentration of 17mg/kg body weight. All mice will be
sacrificed at 20 weeks of age after a 4 week treatment period. Based on previous drug
development preliminary studies and on animal data from our lab, 5-6 mice per group are
sufficient to detect a difference in clinical and experimental data.
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Table A.3 Animal treatment groups for experiment #2.

Strain

Treatment

Age
(weeks)

n

Balb/c

DMSO

10-16

5-6

Balb/c

DCQ

10-16

5-6

Apcmin/+

DMSO

8-20

5-6

Apcmin/+

DCQ

8-20

5-6

Primary outcomes:
Activation of DCQ through HIF-1α pathway:
The chemical structure of 2-benzoyl-3-phenyl 6,7-dichloroquinoxaline 1,4-dioxide is
activated into a free radical intermediate in an electron rich environment. In a hypoxic
environment, this transfer is more likely to occur due to the highly reducing conditions of
hypoxic cells, leading to hypoxic cells acting as a targeting element to the cytotoxicity of
these compounds. Presence of hypoxia inducible factor-1 alpha (HIF-1α) indicates
vasculogenesis and angiogenesis of proliferating cells, a common characteristic of tumor
cells. Intra-tumoral HIF-1α expression will be measured using western blot analysis of
nuclear extracts to determine the level of environmental hypoxia present in the tumors
found in the intestinal and colonic region.
Presence of apoptosis and decreased proliferation:
TUNEL and BRDU staining of xenograft tumors, small intestines, and colon tissue will
be used to analyze the percentage of apoptotic tissue and decreased proliferation. This
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will also allow for analysis of tumor region specificity of DCQ via analysis of healthy
tissue surrounding small-intestine and colon tumors.
Intracellular apoptosis:
Mapping of the intracellular pro-apoptotic and anti-apoptotic genes will be measured
using western blot analysis of cytoplasmic extracts of dephosphorylated-Bad, Bcl-2, Bax,
and cleaved caspase-9.
Secondary Outcomes:
Point of Infiltration: Hematoxylin and Eosin (H&E) staining will be performed on liver
and kidney tissue sections from each animal model to determine point of infiltration of
metastatic tumors.
Specific Methodology Aim #2
Animals: The same mice from Aim #1 will be used for Aim #2. Balb/c male mice will be
bred with female Balb/c mice in the Discovery building Arnold School of Public Health
animal resource facility. Apcmin/+ male mice on a C57BL/6 background will be bred with
female C57BL/6 mice in the Discovery building Arnold School of Public Health animal
resource facility. Resulting heterozygous mice from the Apcmin/+ cross will develop
intestinal and colonic tumors as early as 8 weeks of age and typically have a life span of
20-22 weeks of age. All animals will be housed in standard cages and the room will be
maintained on a 12:12 light:dark cycle with the light period starting at 0700. Mice will be
provided with ad libitum and standard rodent chow (Harlan Teklad Rodent Diet #8604).
Food and water consumption in addition to body weight and clinical score will be
monitored during the course of the study for the Apcmin/+ mice. All animals at time of
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sacrifice are injected with 1mg of BRDU dissolved in phosphate buffered saline (PBS)
and undergo DEXA scan prior to blood draw and cervical dislocation. All animal
experimentation is approved by the University of South Carolina's Institutional Animal
Care and Use Committee. Average mouse weight will be recorded through the first 8
weeks of clinical evaluations (up to 16 weeks of age). At this point, DCQ will be
prepared in DMSO so as to obtain a concentration of 17mg/kg in a 100μl injection
normalized to the average weight of the mice.
Tissue Collection: Mice will be anesthetized via exposure to an isofluorane and oxygen
mixture. Blood will be collected from the retro-orbital sinus using a capillary tube. Blood
will be spun at 4OC, 10,000rpm, for 10 minutes. Plasma will then be pipetted off and
stored at -80OC until analysis. Brain (br), liver (l), kidney (k), spleen (sp), and tumor
xenografts (tmr) from Balb/c mice will be excised, rinsed in PBS, frozen in a dry ice box,
and stored at -80OC until further analysis. Parts of each tissue will also be fixed in 10%
formalin for 24 hours, preserved in 70% ethanol, and then embedded in paraffin wax for
histological sectioning. Small intestine, and colon from the Apcmin/+ mice will be chosen
for sections containing tumors will be fixed in 10% formalin for 24hours, preserved in
70% ethanol, and then embedded in paraffin wax for histological sectioning, brain (br),
liver (l), kidney (k), spleen (sp) will also be collected. Parts of each tissue will also be
excised, rinsed in PBS, frozen in a dry ice box, and stored at -800C until further analysis.
Remaining sections of the small intestine will be rinsed with PBS and opened
longitudinally. Sections will be fixed in 10% formalin for 24 hours and then preserved in
70% ethanol and used for intestinal tumor counts in the Apcmin/+ mice.
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Protein Extraction: Tumor xenografts from Balb/c mice and tumor containing colon
tissue from Apcmin/+ mice will be weighted and homogenized using a dounce
homogenizer. A nuclear extraction kit (ab113474) will be used to homogenize samples
and separate nuclear and cytoplasmic extracts. Samples were weighted between 35 and
45 mg. 5mL diluted ENE1 buffer and 5μL DTT was added to each sample for every gram
on tissue weighted. Once grinded, samples were incubated on ice for 15 minutes and
centrifuged for 10min at 12,000rpm at 4OC. The resulting supernatant was aliquoted as
the cytoplasmic extract and the pellet was kept for nuclear extract. 10μL of 1:1000
diluted DTT in ENE2 and PIC in ENE2 buffer was added to the nuclear pellet for every
2mg of tissue and incubated on ice for 15min with 5sec cortex every 3min. After
incubation, samples were centrifuged for 10min at 14,000rpm at 4OC and resulting
supernatant was aliquoted as nuclear extract. Protein content is determined using the
Bradford Assay (Bradford, 1976).
Western Blot: Nuclear and cytoplasmic protein extracts will be separated by SDS-PAGE
and transferred to nitrocellulose membranes. Bax, Bcl-2, Cleaved caspase-9,
dephosphorylated-Bad, and HIF-1α (nuclear) will be probed for. Tissue homogenates,
60μg for cytoplasmic and 10μg for nuclear, are separated on 10% to 15% SDSpolyacrylamide gels. The gels are transferred to nitrocellulose membranes in 3hrs at
220mA in cold transfer buffer with the transfer apparatus kept in a 40C refrigerator. After
transfer, membranes are washed with dH2Ο and stained with ponceau S to ensure equal
loading and proper transfer. Membranes are blocked in 5% PBS with 0.1% Tween 20
(PBST) milk for 1hr at room temperature and placed in primary antibody at dilutions of
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1:500 to 1:1000 in 5% PBST milk overnight to 72hrs at 40C, HIF-1α requires a 2.5 hour
primary antibody incubation at room temperature. Secondary anti-rabbit IgG-conjugated
secondary antibodies are incubated with the membranes at 1:2000 for 1hr in 5% PBST
milk at room temperature. Enhanced chemiluminescence is used to visualize the
antibody-antigen interactions and develop the blot using the SYNGENE G:BOX Chemi
XX6. Digitally developed blots are analyzed by measuring the integrated optical density
(IOD) of each band using digital imaging software (GeneTools from Syngene,
Cambridge, UK).
Hematoxylin and Eosin Staining (H&E): Transverse sections (~5μm) will be cut from the
paraffin embedded small intestine and colon from the Apcmin/+mice on a rotary
microtome. Cut tissues will be allowed to expand on a 400C -450C water bath and then
attached to (+) charged saline coated microscope slides. Excess paraffin is removed by
placing slides in a 650C oven for 1hr and then stored at 40C until staining. Sections will
be warmed to room temperature for 5-10minutes. Sections will be stained for
morphological analysis using the H&E staining protocol as describe in Aim 1.
TUNEL Assay: Transverse sections (~5μm) will be cut from the paraffin embedded
tumor xenografts, brain, kidney, and liver of Balb/c mice on a rotary microtome. Cut
tissues will be allowed to expand on a 400C -450C water bath and then attached to (+)
charged saline coated microscope slides. Excess paraffin is removed by placing slides in
a 650C oven for 1hr and then stored at 40C until staining. Refrigerated sections will be
warmed to room temperature for 5-10minutes. Sections will be stained for apoptotic
tissue using Apop-Tag kit from Millipore (S7100) as described in Aim 1.
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BrdU Staining: Transverse sections (~5μm) will be cut from the paraffin embedded brain,
kidney, and liver of Balb/c mice on a rotary microtome. Cut tissues will be allowed to
expand on a 400C -450C water bath and then attached to (+) charged saline coated
microscope slides. Excess paraffin is removed by placing slides in a 650C oven for 1hr
and then stored at 40C until staining. Sections will be warmed to room temperature for 510minutes. Sections will be stained for proliferating tissue by tagging of BrdU present in
actively dividing tissue using BRDU IN-SITU Detection Kit from BD Pharmingen
(550803). Sections are deparaffinized using the following washing progression; 3x5min
xylene washes, 2x5min 100% EtOH, 1x3min 95% EtOH, and 1x3min 70% EtOH.
Sections are then washed for 5min in 1X PBS, blocked with 3% H2O2 for 10 minutes at
room temperature, and then washed again 3x5min in PBS. Antigen retrieval is performed
by preparing working solution of retrieval agents from the kit and autoclaving sections in
the Liquid 20 cycle in the Public Health Research Center autoclave. After antigen
retrieval, sections are cooled for 20 min and washed 3x5 min in 1X PBS. Primary
antibody is prepared in a 1:10 dilution with diluent buffer and sections are incubated with
primary antibody for 90 min in a humid chamber at 37 0C. After primary antibody
incubation, sections are washed 3x2 min in 1X PBS and then covered with RTU
Streptavidin-HRP secondary antibody and incubated for 30min in a humid chamber at
room temperature. After incubation sections are washed 4x2min in PBS and detection
reagent DAB is applied to develop the desired intensity of potentially positive cells. After
washing in 3x1min and 1x5 min dH2O, slides are counterstained for 30 sec with 5 %
methyl green and washed in dH2O until counterstain no longer fades. Slides are then
mounted for viewing with Permount mounting media after a minimum 3 hr drying period.
104

Digital photographs will be taken from each section at a 4x, 20x and 40x with a Nikon
E600 Widefield Epifluorescence and Darkfield Microscopy System at the University of
South Carolina School of Medicine, and percent apoptotic tissue will be determined with
imaging software (ImageJ, Bethesda, MD).
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